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ABSTRACT 
 
Quinn, Colin Quinn. Effects of Exercise Training and Doxorubicin on Myogenic 
Regulatory Factors. Published Doctoral Dissertation, University of Northern 
Colorado, 2015. 
 
Doxorubicin (DOX) is a widely used anthracycline antibiotic used to treat a 
number of hematological and solid tumor cancers. Dosage; however, is limited due to its 
toxic effects in healthy tissues. Negative consequences include myotoxicity in skeletal 
muscle, which may limit mobility and activities of daily living. The capacity for skeletal 
muscular regeneration relies heavily of the activity of myogenic regulatory factor (MRF) 
proteins. In vitro experiments with DOX depress expression of MRFs but in vivo 
treatment may elicit different responses. Endurance exercise has been shown to elevate 
MRF expression, and may preserve MRFs following in vivo DOX-treatment. 
Purpose: To determine the effect of short-term endurance training and acute DOX 
administration of skeletal muscle force production and fatigue resistance, levels of lipid 
peroxidation, and expression of MRFs. Methods: Ten week old male Sprague-Dawley 
rats were randomly assigned to one of four groups: sedentary + saline (SED-SAL), SED-
DOX, endurance exercise training + saline (EXER-SAL), or EXER-DOX. Animals 
remained sedentary or performed treadmill training for two weeks. Twenty four hours 
after the activity period, animals were injected with a bolus 15 mg/kg i.p. injection of 
DOX or SAL. Twenty four hours after injection, soleus (SOL) and extensor digitorum 
longus (EDL) skeletal muscles were removed for ex vivo function measures. Analyses of 
lipid peroxidation as malondialdehyde and 4-hydroxyalkenals (MDA + 4-HAE) and 
 iv	  
Western blotting for concentration for MRFs (Myf5, MyoD, myogenin, Mrf4) were 
performed on contralateral muscles.  
Results: Endurance exercise significantly elevated Myf5 and Mrf4 in the SOL (p<0.05). 
No significant differences existed in MRF expression levels in the EDL. No significant 
muscle force production or fatigue resistance differences were identified due to drug or 
activity treatment. MDA + 4-HAE was higher in the SOL of SAL animals (p<0.05) and 
EDL of EXER animals (p<0.05). Conclusion: Short-term endurance exercise effectively 
elevated Myf5 and Mrf4 in slow, oxidative muscle after acute DOX treatment. Endurance 
exercise prior to chemotherapy may augment skeletal muscles’ regenerative capacity 
following treatment, when loss of muscle mass is common. 
  
 v	  
 	
 
TABLE OF CONTENTS 
CHAPTER 
I.         INTRODUCTION ........................................................................................................................ 1 
Background ................................................................................................................................ 1 
Statement of Purpose .................................................................................................................. 3 
Research Hypotheses ................................................................................................................. 4 
Need for Study ........................................................................................................................... 5 
Definition of Terms .................................................................................................................... 7 
II.        REVIEW OF LITERATURE ....................................................................................................... 8 
Doxorubicin ................................................................................................................................ 8 
Reactive Oxygen Species ........................................................................................................... 9 
Deoxyribonucleic Acid Damage .............................................................................................. 12 
Doxorubicin and Skeletal Muscle ............................................................................................ 14 
Skeletal Muscle Growth ........................................................................................................... 16 
Satellite Cells ........................................................................................................................... 18 
Somite Myogenesis .................................................................................................................. 19 
Myogenic Regulatory Factors .................................................................................................. 21 
Doxorubicin and Myogenic Regulatory Factors ...................................................................... 29 
Exercise Preconditioning ......................................................................................................... 31 
Conclusion ................................................................................................................................ 34 
III.       METHODOLOGY .................................................................................................................... 36 
Experimental Design ................................................................................................................ 36 
Animals and Animal Care ........................................................................................................ 37 
Exercise Training Protocol ....................................................................................................... 38 
Drug Treatment ........................................................................................................................ 39 
Isolated Muscle Function ......................................................................................................... 40 
Biochemical Analyses .............................................................................................................. 42 
Statistical Analysis ................................................................................................................... 44 
IV.      RESULTS ................................................................................................................................... 45 
General Observations ............................................................................................................... 45 
Isolated Muscle Function ......................................................................................................... 49 
Biochemical Analyses .............................................................................................................. 58 
Summary .................................................................................................................................. 64 
V.        MANUSCRIPT .......................................................................................................................... 66 
Abstract .................................................................................................................................... 66 
Introduction .............................................................................................................................. 67 
Materials and Methods ............................................................................................................. 69 
Results ...................................................................................................................................... 75 
Discussion ................................................................................................................................ 92 
REFERENCES ...................................................................................................................................... 98 
APPENDIX A - IACUC Approval ...................................................................................................... 115 
APPENDIX B - Pilot Study ................................................................................................................. 117 
 vi	  
 
 
 
 
LIST OF TABLES 
TABLE 
1.1     Abbreviations ................................................................................................................................. 6 
3.1     Treadmill exercise training protocol ............................................................................................ 39 
4.1     Animal Characteristics ................................................................................................................. 46 
4.2     Tissue mass relative to body mass ............................................................................................... 48 
4.3     SOL muscle twitch forces ............................................................................................................ 50 
4.4     EDL muscle twitch forces ............................................................................................................ 52 
4.5     Lipid peroxidation levels ............................................................................................................. 58 
4.6     SOL MRF levels .......................................................................................................................... 60 
4.7     EDL MRF levels .......................................................................................................................... 60 
5.1     Treadmill exercise training protocol ............................................................................................ 70 
5.2     Animal Characteristics ................................................................................................................. 75 
5.3     Tissue mass relative to body mass ............................................................................................... 77 
5.4     SOL muscle twitch forces ............................................................................................................ 79 
5.5     EDL muscle twitch forces ............................................................................................................ 81 
5.6     Lipid peroxidation levels ............................................................................................................. 86 
5.7     SOL MRF levels .......................................................................................................................... 88 
5.8     EDL MRF levels .......................................................................................................................... 88 
 
 
 
 
 
 vii	  
 
 
LIST OF FIGURES 
FIGURE 
2.1     Structure of DOX ........................................................................................................................... 9 
2.2     Hierarchy of transcription factors regulating progression through the myogenic lineage ........... 22 
2.3     Satellite cell activation and differentiation in myogenesis and regeneration  ............................. 23 
2.4     Sites of MEF2 proteins influence in myogenesis  ....................................................................... 29 
3.1     Experimental design for treatments ............................................................................................. 37 
4.1     Change in body mass following injections .................................................................................. 47 
4.2     Tissue mass at time of sacrifice. .................................................................................................. 48 
4.3     Tissue mass relative to body mass. .............................................................................................. 49 
4.4     SOL Maximal twitch force values. .............................................................................................. 51 
4.5     EDL Maximal twitch force values. .............................................................................................. 53 
4.6     SOL fatigue resistance ................................................................................................................. 55 
4.7     EDL fatigue resistance ................................................................................................................. 57 
4.8     Lipid peroxidation levels in hindlimb muscles ............................................................................ 59 
4.9     Myf5 expression levels ................................................................................................................ 61 
4.10   MyoD expression levels ............................................................................................................... 62 
4.11   Myogenin expression levels ......................................................................................................... 63 
4.12   Mrf4 expression levels. ................................................................................................................ 64 
5.1     Change in body mass following injections .................................................................................. 76 
5.2     Tissue mass at time of sacrifice. .................................................................................................. 77 
5.3     Tissue mass relative to body mass. .............................................................................................. 78 
5.4     SOL Maximal twitch force values. .............................................................................................. 80 
5.5     EDL Maximal twitch force values. .............................................................................................. 82 
5.6     SOL fatigue resistance ................................................................................................................. 83 
5.7     EDL fatigue resistance ................................................................................................................. 85 
5.8     Lipid peroxidation levels in hindlimb muscles ............................................................................ 87 
5.9     Myf5 expression levels ................................................................................................................ 89 
5.10   MyoD expression levels ............................................................................................................... 90 
5.11   Myogenin expression levels ......................................................................................................... 91 
5.12   Mrf4 expression levels. ................................................................................................................ 92 
 
 
 
 
	 1 
	
 
 
 
CHAPTER I 
INTRODUCTION 
Background 
 Muscle weakness and subsequent deterioration in activities of daily living are 
common side effects of chemotherapy treatments prescribed to cancer patients (Bonifati 
et al., 2000; Burckart, Beca, Urban, & Sheffield-Moore, 2010; Knobel et al., 2001). The 
commonly used anthracycline antibiotic, doxorubicin (DOX; trade name: Adriamycin®) 
has been shown to cause severe to fatal consequences associated with its cardiotoxic 
nature. Free radicals formed by iron-catalyzed reactions are implicated in nuclear and 
mitochondrial damage inducing cell death (Bagchi, Bagchi, Hassoun, Kelly, & Stohs, 
1995; DeAtley et al., 1999; Rapozzi et al., 1998; Stathopoulos et al., 1997). Much of the 
existing literature surrounding DOX-induced injury focuses on effects seen in the heart. 
More recently, research has elucidated serious skeletal muscle harm, decreasing muscle 
size and function in response to DOX exposure (Doroshow, Tallent, & Schechter, 1985; 
Gilliam et al., 2009; Gilliam et al., 2013; Gilliam, Moylan, Callahan, Sumandea, & Reid, 
2011). Previous research has demonstrated the beneficial influence of endurance exercise 
preconditioning in mitigating the negative cardio- and myotoxic consequences of DOX 
treatment (Ascensão, Oliveira, & Magalhães, 2012; Chicco, Schneider, & Hayward, 
2006; Hayward, Lien, Jensen, Hydock, & Schneider, 2012; Hydock, Lien, Jensen, 
Schneider, & Hayward, 2011b). 
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 Skeletal muscle comprises a large part of the human body, responsible for posture 
and locomotion. It is unique in its plasticity to alter its form following various stimuli. In 
adult muscle, myogenic regulatory factors (MRFs) guide satellite cells to restore muscle 
integrity in response to damage and stress, such as exercise. Activated satellite cells, 
expressing primary MRFs, form myoblasts, and differentiate into myotubes in response 
to secondary MRFs and reconstitute muscle fibers. The ability of skeletal muscle to repair 
itself and retain structure relies heavily on functional MRF proteins.  
 In vitro DOX exposure has been shown to decrease the ability of myoblasts to 
differentiate into myotubes (Kurabayashi, Jeyaseelan, & Kedes, 1993). Additionally, 
MRF mRNA expression is compromised under the same conditions with an up-regulation 
of the MRF inhibitor, Id (Kurabayashi, Jeyaseelan, & Kedes, 1994). DOX has been 
shown to induce oxidative stress, leading to cellular damage and single-stranded DNA 
breaks. Beyond oxidative damage, genotoxic stress attributed to DOX leads to double-
stranded DNA breaks. The primary MRF, MyoD, is fundamentally involved in myoblast 
DNA repair (Kobayashi, Antoccia, Tauchi, Matsuura, & Komatsu, 2004). Its presence, 
along with the other MRFs, is critical for skeletal muscle regeneration following 
chemotherapy treatment including DOX. Although MRF mRNA has been broadly 
investigated, functional protein expression has been less examined. Functional MRF 
protein may be enhanced with endurance exercise prior to drug treatments.  
 In a pilot study (see Appendix B), rat skeletal muscle was examined three days 
following DOX or saline injections. Sedentary animals treated with DOX versus saline 
injections displayed differential expressions of MRFs in soleus (SOL) and extensor 
digitorum longus (EDL) muscles. Myf5 and MyoD were lower in SOL of animals 
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receiving DOX, while myogenin and Mrf4 were significantly greater. Myf5 and MyoD 
increased in EDL and Mrf4 decreased following DOX injections. Prior endurance 
exercise training may influence the expression of MRFs in skeletal muscle. Following 
endurance training, SOL of rats demonstrated elevated levels of myogenin (Siu, Donley, 
Bryner, & Alway, 2004). In combination with elevated antioxidant enzymes due to short-
term aerobic exercise, increased MRF protein may effectively mitigate the skeletal 
muscle dysfunction attributed to DOX treatment and enhance subsequent repairs. 
Statement of Purpose 
 The purpose of this study was to investigate the effects of in vivo DOX 
administration on skeletal muscle force production and fatigue resistance, oxidative 
damage, and expression of MRFs (MyoD, Myf5, myogenin, & Mrf4). A secondary 
purpose of the study was to examine if prior short-term exercise provides protection 
against DOX-induced muscle dysfunction, lipid peroxidation and MRF alterations in 
skeletal muscle. Whether MRF protein expression affects muscle function or is, itself, 
affected by oxidative stress may be elucidated with this research. The study addressed 
myogenic mechanisms associated with adult muscle regenerative capacity occurring with 
DOX treatment. An additional goal of the study was to identify whether short-term 
aerobic exercise intervention can be used to offset muscular dysfunction afflicting cancer 
patients. 
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Research Hypotheses 
Specific Aim 1 
The purpose of the first specific aim was to identify the effects of DOX treatment and 2-
week endurance training on ex vivo skeletal muscle force production and fatigue 
resistance. 
 
H1 DOX treatment will impair skeletal muscle twitch force production and 
fatigue resistance when analyzed 1 day following DOX injection. 
 
H2 Short-term endurance exercise will minimize DOX-induced myotoxic 
function. 
 
Specific Aim 2 
The second specific aim was to determine oxidative stress in response to DOX and 
exercise in skeletal muscles. 
 
H3 DOX treatment will increase lipid peroxidation levels 1 day following DOX 
injection. 
 
 H4 Short-term endurance exercise will minimize DOX-induced lipid 
peroxidation in both SOL and EDL. 
 
 
Specific Aim 3 
The third specific aim was to identify the effect of short-term exercise and acute, in vivo 
DOX treatment on MRF expression in hindlimb muscles. 
 
H5 Primary MRF protein (Myf5 and MyoD) concentrations will significantly 
decrease in slow, oxidative muscles (SOL) and increase in fast, glycolytic 
muscles (EDL) following in vivo DOX treatment compared with control 
animals. 
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H6 Secondary MRF protein (myogenin and Mrf4) concentrations will 
significantly increase in SOL and decrease in EDL following in vivo DOX 
treatment compared with control animals. 
 
H7 Prior endurance exercise will attenuate MRF alterations associated with DOX 
treatment. 
Need for Study 
 Skeletal muscle weakness following chemotherapy is well documented. Decreases 
in activities of daily living and susceptibility to falls can have dire consequences. Recent 
literature has shown time to chemotherapy can have adverse outcomes, especially with 
higher graded cancers (de Melo Gagliato et al., 2014). Although research has 
demonstrated chronic endurance exercise to provide a protective effect, time does not 
often allow for an extended exercise-training period. DOX prescription in chemotherapy 
is quite common, and patients often experience later cardiotoxicity, but patients also 
exhibit skeletal muscle degeneration and dysfunction. The benefit of exercise 
preconditioning has proven useful in protecting cardiac and skeletal muscles from ills 
associated with DOX treatment, but time to chemotherapy may not afford such a time 
until treatment. Designing a useful, short-term aerobic exercise intervention to maintain 
skeletal muscle form and function may improve the adaptive capacity of muscle 
following DOX treatment. Myogenic regulatory factors play an integral role in the 
regeneration of adult muscle tissue, and methods to maintain their expression may afford 
greater quality of life following chemotherapy. Short-term exercise preconditioning may 
offer skeletal muscles the capability to combat the oxidative and genotoxic stress 
associated with doxorubicin treatment.
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Table 1.1  	
Abbreviations 
4+HAE = 4-Hydroxyalkenals ABL = Abelson murine Leukemia 
ANOVA = Analysis of Variance Bax = Bcl-2-associated X protein  
BCA = Bicinchronic Acid bHLH = Basic Helix-Loop-Helix 
C2C12 = Mouse myoblast cell line Ca2+ = Calcium 
Caspase = Cysteine-aspartic protease CHF = Congestive Heart Failure 
CO = Carbon monoxide DDR = DNA Damage Response 
DNA = Deoxyribonucleic Acid DOX = Doxorubicin 
DSB = Double-Strand Break ECL = Enhanced Chemiluminescence 
EDL = Extensor Digitorum Longus EXER = Exercise 
GPX = Glutathione Peroxidase H2O2 = Hydrogen Peroxide 
HRP = Horseradish Peroxidase Hz = Hertz 
i.p. = Intraperitoneal Id = Inhibitor of DNA binding 
K+ = = Potassium LPO = Lipid Peroxidation 
mA = Milliampere MCK = Muscle Creatine Kinase 
MDA = Malondialdehyde MEF2 = Myocyte Enhancer Factor 2 
MPC = Myogenic Progenitor Cell MRF = Myogenic Regulatory Factor 
mRNA = Messenger RNA MyHC = Myosin Heavy Chain 
Nbs1 = Nijmegen Breakage Syndrome 1 gene O2- = Superoxide Anion 
OH = Hydroxyl radical Pax = Paired-homeobox 
PUFA = Polyunsaturated Fatty Acid PVDF = Polyvinylidene Fluoride 
RIPA = Radioimmunoprecipitation Assay RNA = Ribonucleic Acid  
ROO- = Peroxyl ROS = Reactive Oxygen Species 
SAL = Saline SC = Satellite Cell 
SDS-PAGE = Sodium Dodecyl Sulfate-                
Polyacrylamide Gel Electrophoresis 
SED = Sedentary 
SHH = Sonic Hedghog SOD = Superoxide Dismutase 
SOL = Soleus SR = Sarcoendoplasmic Reticulum 
SSB = Single-Strand Break TBST = Tris-Buffered Saline with Tween20 
TM = Treadmill TNF = Tumor Necrosis Factor 
TOP2 = Topoisomerase II V = Volt 
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Definition of Terms 	
Anthracycline – Class of antibiotic used in chemotherapy derived from Streptomyces 
bacterium 
Antineoplastic – Preventing the growth and spread of tumors or malignant cells 
Apoptosis – Process of programmed cell death, marked by morphological changes and 
DNA fragmentation 
Caspase – Cysteine protease involved in direction of apoptosis, necrosis, and 
inflammation 
Double-strand break – Condition where both strands of DNA double helix have been 
individually cleaved without separation of the two strands 
Doxorubicin – Bacterial antibiotic used in the treatment of various cancers 
Embryogenesis – Formation and development of an embryo 
Genotoxic stress – Damage to the genome of an organism as result of a genotoxin 
Genotoxin – Substance capable of causing damage to cellular DNA and causing 
mutations or cancer 
Myogenesis – Formation and growth of muscle tissue  
Oxidative stress – Damage caused to cells or tissue as result of reactive oxygen species 
Redox cycling – Reactions involving the transfer of electrons, resulting in change 
between reduced and oxidized states 
Single-strand break – Cleavage of only one of the two strands of DNA, while both 
strands remained attached to one another 
Zymogen – Inactive enzyme precursor
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CHAPTER II 
REVIEW OF LITERATURE 
Doxorubicin 
Doxorubicin (DOX; trade name: Adriamycin®) is a widely used antineoplastic 
for treating both solid and hematological cancers. Clinically, DOX is administered 
intravenously (i.v.) and in some cases directly into the abdomen via intraperitoneal (i.p.) 
injections (Chabner, Ryan, Paz-Ares, & Garcia-Carbonero, 2001; Chu & DeVita, 2006; 
Sugarbaker, 2009; Van der Speeten, Stuart, Mahteme, & Sugarbaker, 2009). 
Unfortunately, DOX use is limited due to undesirable effects on cardiac muscle, 
including contractile dysfunction, dilated cardiomyopathy, and congestive heart failure 
(CHF) (Singal, Li, Kumar, Danelisen, & Iliskovic, 2000; Singal & Iliskovic, 1998). 
Additionally, skeletal muscle dysfunction is observed following DOX administration. 
DOX-induced skeletal myopathies can lead to severe respiratory and locomotor 
impairments (Kavazis, Smuder, & Powers, 2014). 
The proposed mechanisms behind the antineoplastic action of DOX suggest that 
DOX inhibits DNA synthesis, forms free radicals, promotes lipid peroxidation, binds and 
alkylates DNA, interferes with DNA separation activity, directly affects cell membranes, 
initiates DNA damage via topoisomerase II, and signals apoptosis (Gewirtz, 1999; 
Minotti, Menna, Salvatorelli, Cairo, & Gianni, 2004). Anthracyclines, like DOX, are 
prone to generate reactive oxygen species (ROS) when mitochondrial enzymes interact 
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with a quinone ring C of DOX (Figure 2.1), releasing electrons that are captured by 
oxidizing agents (i.e., oxygen). Molecular oxygen is then reduced to ROS like 
superoxide, hydroxyl and peroxide radicals. Elevated levels of ROS lead to lipid 
peroxidation, DNA damage and cell apoptosis, arresting malignant cancer growth. These 
effects, however, are not limited to cancerous cells, and healthy cells are also affected. 
Because of this unwanted side effect, dosages of DOX are limited to minimize side 
effects.  
 
 
 
Figure 2.1. Structure of DOX (Minotti et al., 2004) 	
Reactive Oxygen Species 
Oxidative stress is a condition in which the cellular balance of pro-oxidants 
outweighs antioxidants. Oxidative stress primarily occurs when oxygen free radicals 
accumulate within the body. Oxygen free radicals are small, diffusible molecules with an 
Quinone ring C 
cycling between 
oxidized and 
reduced states 
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unpaired electron, such as hydrogen peroxide (H2O2), superoxide anion (O2-), peroxyl 
(ROO-), or hydroxyl radical (OH). Accumulated oxidative damage has been shown to 
induce mitochondrial damage and apoptosis, while furthering the formation of ROS 
(Valko et al., 2007).  
Any protein or enzymatic system, which transfers electrons, can form ROS by 
donating or receiving electrons from oxygen or oxygen-derived compounds. Therefore, 
ROS byproducts can be found in mitochondria, peroxisomes, cytochrome p450 reactions 
and phagocytic immune responses. Flavoenzymes use NADPH as an electron source in 
redox cycling. An electron is transferred from NADPH to the quinone of anthracyclines, 
reducing it to a semiquinone state. The semiquinone rapidly returns to its parent state 
once the electron is donated to oxygen, forming superoxide (O2-) (Gutierrez, 2000). 
Following DOX administration, ROS are produced largely in the mitochondria, with 
redox cycling at complex I of the electron transport chain (Minotti et al., 2004). At this 
stage, DOX is converted to a semiquinone reactive, forming O2- and subsequent H2O2 
and OH (Davies & Doroshow, 1986; Doroshow & Davies, 1986).  
In the normal physiological environment, oxygen free radicals are produced as 
part of oxidative metabolism. In addition to inducing apoptosis, ROS can signal gene 
expression as second messengers. ROS production is a major regulator of signaling 
pathways promoting skeletal muscle adaptations following exercise (Franco, Odom, & 
Rando, 1999; Li, Chen, Li, & Reid, 2003). The levels of ROS, however, must be 
maintained at homeostatic levels to allow cellular processes of muscle growth and 
differentiation. Although exercise leads to a spike in oxygen free radical production, 
antioxidant enzymes are increased to better handle radicals and shift levels toward a 
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healthy balance. The naturally occurring antioxidant enzymes in skeletal muscle include 
catalase, glutathione peroxidase (GPX), and superoxide dismutase (SOD). Under normal 
conditions, ROS generation is significantly higher in type IIB muscle fibers than type I or 
type IIA, whereas ROS clearance rates are highest in type I fiber due to higher levels of 
antioxidant enzymes (Anderson & Neufer, 2006). During conditions of inflammation and 
disease, ROS concentrations are elevated beyond the capacity of antioxidant handling.  
ROS also affect the regulation of K+ channels, plasma membrane Ca2+ channels 
and intracellular Ca2+ channels in muscle tissues (Hool, Di Maria, Viola, & Arthur, 2005; 
Tang, Santarelli, Heinemann, & Hoshi, 2004). Maintenance of redox potential in 
myocytes is important because hypoxic conditions will inactivate K+ channels, 
decreasing carbon monoxide (CO) production and muscle metabolism while increasing 
ROS generated. This condition fails to maintain redox homeostasis and results in cell 
injury or dysfunction (Hoshi & Lahiri, 2004). 
Uncontrolled oxidative stress acts as a feed-forward process, whereby the 
increased concentration of ROS enhances intracellular and extracellular production of 
ROS. Subsequent deleterious effects include lipid perodixation, damage to cell 
membranes and organelles, disrupted signaling pathways, apoptosis, and muscle atrophy. 
Lipid peroxidation (LPO) is a chain reaction initiated and furthered by oxygen free 
radicals. ROS target double bonds of polyunsaturated fatty acids (PUFAs), and 
compromise the integrity of mitochondrial membranes, which contain high levels of 
PUFAs (Chance, Sies, & Boveris, 1979).  
When these mitochondrial membranes become perforated due to the pro-oxidant 
state, cytochrome c is released into the cytosol inducing caspase 9 signals for intrinsic 
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cell apoptosis. Once inside the cytosol, cytochrome c binds to apoptotic protease 
activating factor 1, allowing for the additional binding of a pro-caspase 9 zymogen in the 
presence of adenosine triphosphate (ATP). This newly formed complex autoactivates 
caspase 9, and signals caspase 3 downstream, inducing programmed cell death. Hydrogen 
peroxide (H2O2) and superoxide (O2-) may activate the p53 gene inducing apoptotic 
events as well. p53 directly activates the Bax gene (apoptotic factor), which binds to a 
mitochondrial membrane-bound receptor and opens channels leading to a release of 
cytochrome c and pro-caspase 9 (Chandra, Samali, & Orrenius, 2000; Feng Gao et al., 
2001). This mitochondrial (intrinsic) pathway differs from the death receptor pathway, 
whereby signals, such as TNFα, bind to a plasma membrane-bound Fas ligand receptor, 
and stimulate apoptosis via caspase 8 (Fulda & Debatin, 2006). Additionally, activated 
p53 translocates to the nucleus where it induces gene expression (p21) preventing cell 
division (Cui, Schroering, & Ding, 2002). 
Deoxyribonucleic Acid Damage 
Beyond membrane damage, uncontrolled oxidative stress may augment or 
individually disrupt deoxyribonucleic acid (DNA) transcription and synthesis. Hydroxyl 
radicals (OH) have been shown to cause DNA base modification or fragmentation (Van 
Remmen, Hamilton, & Richardson, 2003). Disruption of the genome and replication 
processes following radiation and chemotherapy is referred to as “genotoxic stress” 
(Simonatto et al., 2011). The main forms of DNA damage likely to occur following DOX 
administration are ROS-induced single-strand break (SSB), topoisomerase II-mediated 
double-strand break (DSB), and apoptotic DNA fragmentation (Swift, Rephaeli, 
Nudelman, Phillips, & Cutts, 2006). DOX treatment causes early event H2O2 
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accumulation, which may be responsible for oxidative DNA lesions in cardiomyocytes 
(L'Ecuyer et al., 2006). These oxidative lesions are readily repaired upon removal of 
oxidants by free radical scavengers, such as N-acetyl cysteine (L'Ecuyer et al., 2006). 
Non-oxidative, DOX-induced DNA damage, however, is less prone to rapid repair. 
Specifically, anthracycline-induced DNA lesions include oxidized pyrimidines and 8-
hydroxyguanine (L'Ecuyer et al., 2006).  
When DNA templates are damaged (i.e., lesions), cells stall at checkpoints before 
replication and mitotic chromosome separation at the transition from G1 to S phase and 
G2 to M phase (fork stalls). These delays facilitate the maintenance of proper DNA 
sequences and prevention of accumulated DNA alterations (Nelson & Kastan, 1994). At 
the G1 checkpoint, the tumor suppressor protein, p53, acts as a major regulator. 
Following DNA damage, p53 levels rapidly increase and signal transduction pathways 
lead to G1 cycle arrest or apoptosis (Kastan, Onyekwere, Sidransky, Vogelstein, & Craig, 
1991). In myoblasts, p53 transactivates p21 to arrest the cell cycle following DOX 
treatment. Terminally differentiated myotubes, however, do not exhibit p53 activation of 
p21 or Bax genes, yet cell death occurs when exposed to DSB-inducing agents, like DOX 
(Fortini et al., 2012). 
Intercalative antibiotics, such as DOX, generate protein-linked DNA strand 
breaks via topoisomerase II (TOP2) inhibition (Tewey, Rowe, Yang, Halligan, & Liu, 
1984). Topoisomerases are enzymes that regulate the intertwining of DNA double-helical 
structure. Mammalian TOP2 catalyzes topological isomerization reactions, via binding 
DNA and passing the DNA strand to correct base pair structures and over-winding. The 
TOP2-DNA union is referred to as a “cleavable complex.” DOX stabilizes these 
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topoisomerase-DNA complexes, stalling replication forks. The stabilization of the 
“cleavable” TOP2-DNA complex pauses strand passing activity, and prevents DNA 
replication and RNA synthesis (Tewey et al., 1984). Beyond stabilizing the complex, 
DOX intercalates elsewhere on DNA, binding tightly and further damaging strand 
integrity. Furthermore, inability to cleave the stabilized complex leaves a lesion, which 
results in a DNA DSB (Swift et al., 2006). In response to DNA damage, an apoptotic 
reaction is signaled. 
DNA damage response (DDR) is a complex network involving repair factors and 
cell cycle regulators when genotoxic stress is induced (Ciccia & Elledge, 2010). 
Checkpoints for DNA damage repair are at transitions from G1/S and G2/M phases 
(Simonatto et al., 2011). If repair is not successfully completed, cells are destined to 
apoptotic fates. Oxidative stress in terminally differentiated muscle cells may decrease 
base excision repair (BER) capacity and lead to accumulation of SSBs, but cell death is 
not inevitable in post-mitotic cells. DOX-induced muscle cell death is mainly attributed 
to the activation of p53 by topoisomerase II DSB (Fortini et al., 2012). Similarly, Müller 
and colleagues (1997) report apoptosis in skeletal muscle to be dependent on RNA 
synthesis disruption rather than oxidative damage, which requires higher concentrations 
to signal apoptosis. When DNA chromatin is damaged, histone H2AX is phosphorylated 
and forms foci at the injured site (Kobayashi et al., 2002). 
Doxorubucin and Skeletal Muscle 
The toxic effects of DOX on cardiac muscle are well documented, but similar 
parallels in characteristics of DOX-induced changes have been shown following single 
i.p. DOX injections with losses in skeletal muscle mass and myofibrillar disorganization 
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(Doroshow, Tallent, & Schechter, 1985). Both Type 1 and Type 2 muscle fibers decrease 
in size following single limb DOX perfusion (Bonifati et al., 2000). Additionally, DOX 
may upset excitation-contraction (EC) coupling mechanisms by altering SR Ca2+ 
transport, thereby reducing muscle force production (Hidalgo, Bull, Behrens, & Donoso, 
2004; van Norren et al., 2009). Studies investigating cardiac muscle have shown no 
changes in Ca2+ sensitivity, but found inhibition of SR uptake and release following DOX 
treatments (Chugun et al., 2000).  
Our lab demonstrated that skeletal muscle, similar to cardiac tissue, exhibited 
severe functional declines in a time-dependent fashion following DOX injections 
(Hayward et al., 2013). Additionally, proteolysis of skeletal muscle occurs following 
DOX injections, resulting in degradation of myofibrillar actin (Smuder, Kavazis, Min, & 
Powers, 2011b). Subsequently, this proteolysis may be linked to decreased muscle mass, 
as muscle cross-sectional area is reduced following DOX administration (Mcloon, 
Falkenberg, Dykstra, & Iaizzo, 1998). Functionally, patients who were treated with DOX 
displayed reduced handgrip strength and quicker rates of fatigue (Stone et al., 1999). 
Although i.p. DOX treatment does not affect limb muscles as severely as the heart or 
diaphragm, cellular disruption, catabolism, and functional declines are evident 
(Doroshow et al., 1985; Gilliam et al., 2009; Gilliam et al., 2012). Furthermore, DOX 
treatment down-regulates contractile gene expression to include myosin-binding protein 
H, myosin light chain 4, and troponin T type 1 (Simonatto et al., 2011). Clinical DOX 
treatment clearly initiates skeletal myotoxic consequences. 
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Skeletal Muscle Growth 
Skeletal muscle is a dynamic, plastic tissue adept to hypertrophy in response to 
growth factors, nutrition, and exercise (Evans, 2004). The growth and development of 
skeletal muscle is mediated by a process whereby myoblasts produce myogenic 
regulatory factors (MRFs), which allow further development and differentiation of a large 
number of different cell types into muscle (Lowe & Alway, 1999; Megeney & Rudnicki, 
1995).  The MRFs are a family of basic helix-loop-helix (bHLH) muscle specific 
regulatory proteins expressed exclusively by myonuclei and activated by satellite cells. 
MRFs contain a basic region that facilitates DNA binding and HLH domain mediating 
dimerization (Davis, Cheng, Lassar, & Weintraub, 1990). The HLH motif in MRFs 
consists of α-helices, separated by a variable loop region. The consensus DNA sequence 
5’-CANNTG-3’, referred to as an “E-box,” serves as the DNA target site for the basic 
region (Murre et al., 1989). Activation of gene expression by MRFs requires 
heterodimerization with another bHLH protein, which is typically from the E-protein 
family. The bHLH E-proteins, E12 and E47, are 2 splice variants of the E2A gene that 
are ubiquitously expressed and most frequently dimerize with MRFs (Lassar et al., 1991).  
Once MRF-E protein heterodimers are formed, the DNA-binding domain binds to 
a target E-box (CANNTG) site. The E-box sequence of DNA is found in the regulatory 
region of many skeletal muscle-specific genes (Siu, Donley, Bryner, & Alway, 2004). 
Downstream targets are then activated, leading to the expression of muscle structural 
genes (contractile proteins) and generation of differentiated muscle phenotypes. 
Additionally, the MRFs interact with MEF2 family of MADS-box transcription factors, 
including MEF2A, -B, -C and –D. Not all skeletal muscle genes have E-boxes, and may 
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require other factors to activate transcription (Hauschka, 1994). MEF2 factors bind to 
MRF basic domains increasing conversion of non-muscle cells with MRFs (Molkentin, 
Black, Martin, & Olson, 1995). MRFs autoregulate their own expression and induce 
MEF2 expression. MEF2 factors bind to promoters of myogenic bHLH genes, 
reinforcing their maintenance and transcription in a positive feedback fashion (Olson, 
Perry, & Schulz, 1995). 
MRFs include the transcription factors: MyoD, Myf5, myogenin and Mrf4. These 
transcription factors act by increasing satellite cell proliferation and differentiation into 
myoblasts. Functions of MRFs overlap, but are distinct in function with one rescuing 
myoblast development in the absence of individual factors. MyoD and Myf5 are 
expressed in proliferating myoblasts, and are referred to as primary MRFs. Myogenin and 
Mrf4, or secondary MRFs, are present in myocytes in the process of terminal 
differentiation. MyoD and Myf5 are expressed initially in proliferating myoblasts and 
differentiating muscle, promoting entry into the cell cycle (Sabourin & Rudnicki, 2000). 
Myogenin and Mrf4 are expressed later following myocyte fusion, promoting 
differentiation and cell cycle exit (Hinterberger, Sassoon, Rhodes, & Konieczny, 1991). 
Upstream of MRFs, the paired-box (Pax) family of transcription factors signal the 
activation of satellite cells for growth and repair of skeletal muscles. Specifically, Pax3 
and Pax7 are expressed uniquely in satellite cells. Upon injury, Pax7-expressing satellite 
cells migrate to the damaged tissue. The Pax transcription factor levels are reduced with 
concurrent increase of Myf5 and MyoD, leading to differentiation of myoblasts (Braun, 
Rudnicki, Arnold, & Jaenisch, 1992; Rudnicki et al., 1993). Cells expressing Myf5 and 
MyoD expand and proliferate myoblasts. After cue for differentiation, myoblasts exit the 
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cell cycle as myotubes and express myogenin and p21 (Halevy et al., 1995). The 
terminally differentiated, multinucleated myotubes are distinguished by expression of 
myosin heavy chain (MyHC) and troponin T. 
In the event that p53 signals nuclear apoptosis in skeletal muscle cells, the whole 
myofiber is not necessarily degraded. Due to the multinucleated nature of skeletal muscle 
fibers, individual myonuclear apoptosis can occur without complete cell death (Primeau, 
Adhihetty, & Hood, 2002). The nuclei selected for apoptosis are degraded without 
affecting the survival of other nuclei in the shared cytoplasm or causing cell destruction 
(Primeau et al., 2002). 
Satellite Cells 
The regenerative properties of skeletal muscle are due to progenitor cells known 
as satellite cells (SCs). In adult muscle, SCs are small mononucleated skeletal muscle 
precursor cells between the basal lamina of the muscle and sarcolemma of myofibers. In 
adult tissue, approximately 5% of myonuclei in muscle fibers are within SCs (Bischoff, 
1994; Zammit & Beauchamp, 2001). These unstressed cells are quiescent and arrested at 
an early stage of the myogenic program. Following injury or in response to increased 
functional demand, SCs become activated, rapidly divide, and exit the cell cycle. Next, 
SCs migrate to the site of injury, proliferate, and differentiate into myoblasts. 
Cytoplasmic volume increases and organelles develop, and the SC nuclei become 
myonuclei. The myoblasts fuse to one another, forming multinucleated myotubes, or fuse 
in place of damaged fibers, repairing damaged myofibers (Moss & Leblond, 1971). Some 
of the proliferating SCs do not differentiate but rather remain quiescent in the G0/G1 
phase of the cell cycle. Adult myonuclei are unable to divide, so repair and growth of 
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muscle depends on the availability of SCs to provide new myonuclei in adult muscle 
fiber. Due to the insulated position of SCs, they are shielded from environmental 
exposure such as genotoxic stress experienced with DOX (Pallafacchina et al., 2010). 
Frequency of SCs differs among muscle fiber types, where red, oxidative fibers 
have more than white, glycolytic fibers. Additionally, myonuclear density is higher in the 
red fibers, likely due to higher metabolic activity. Although MRFs can induce other cell 
types (fibroblasts, etc.) to a myogenic fate, SCs provide the largest pool of new myogenic 
precursors in hypertrophying muscle fibers (Moss & Leblond, 1971; Schiaffino, 
Bormioli, & Aloisi, 1976). 
Pax7 is a transcription protein expressed in cells that lie beneath the basal lamina, 
and Pax7-null animals have no SCs (Seale et al., 2000). A number of SCs retain their 
Pax7 expression while down-regulating MyoD, reversibly exit the cell cycle, and 
reposition to the basal lamina until needed (Zammit et al., 2004). Continued Pax7 
expression inhibits the pathway to myogenic fate (Wang & Conboy, 2010). After 
activation and prior to differentiation, SCs express either Myf5 or MyoD (Cornelison & 
Wold, 1997). 
Somite Myogenesis 
Vertebrate skeletal muscle is derived from somites formed during embryogenesis. 
Somites are epithelial structures segmented from the paraxial mesoderm. The dorsal 
portion of the somite is referred to as the dermomytome, which is comprised of dermal 
and muscle progenitor cells (MPCs), whereas the ventral side will form the vertebral 
column and ribs. The edges of the dermomyotome transitions from epithelial to 
mesenchyme tissue, giving rise to the myotome, where the first differentiated myofibers 
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exist. The dorsomedial (epaxial) region of the dermomyotome and myotome will become 
the axial muscles of the back, while the ventrolateral (hypaxial) somite will generate 
other trunk and limb muscles (Buckingham, 2001). At this stage, MPCs do not express 
any MRFs or other skeletal muscle markers. Myogenesis in the myotome is induced by 
both the notochord and neural plate cooperatively through members of the Wnt family of 
growth factors to include Sonic hedgehog (Shh), Wnt-1, -3, and -4 proteins. Somatic cell 
precursors, originating from the dermomyotome, migrate to limbs to commit to myogenic 
fates (Brand-Saberi & Christ, 1999). 
Gene ablation models have determined much of what is known about myogenesis, 
whereby genes are deleted to determine the function served. MPCs are distinguished by 
the presence of Pax3 and Pax7. When Pax3 fails to be expressed, muscle development is 
impaired, with a complete loss of the hypaxial somite and loss of limb and some trunk 
muscles (Dietrich, Schubert, Gruss, & Lumsden, 1999; Relaix, Rocancourt, Mansouri, & 
Buckingham, 2004). In the absence of Pax3, epaxial muscles are less affected, but death 
occurs mid-gestation (Chi & Epstein, 2002). Later in development, Pax7 becomes more 
important, as MPCs cannot begin myogenic development without it. Lack of both Pax3 
and Pax7 in MPCs will not allow entrance to myogenic lineage. The four bHLH 
transcription factors, MyoD, Myf5, myogenin, and Mrf4, follow the Pax genes in the 
myogenic development of the myotome. 
Myogenic identity of cells is signaled by the determinant transcription factors, 
Myf5 and MyoD. Individual disruption of Myf5 or MyoD in mice delays formation of 
hypaxial and epaxial muscles, but no gross defects are evident in differentiation due to 
functional redundancy of primary MRFs (Braun et al., 1992; Rudnicki, Braun, Hinuma, 
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& Jaenisch, 1992). With losses in both Myf5 and MyoD, mice show reduced muscle 
mass due to defective myoblast formation (Rudnicki et al., 1993). Additionally, severe 
defects occur when differentiating secondary factors fail to be expressed. When 
myogenin is absent in mice, myofiber formation is compromised causing animals to die 
perinatally (Hasty et al., 1993; Nabeshima et al., 1993; Venuti, Morris, Vivian, Olson, & 
Klein, 1995). Failure to express the Mrf4 gene leads to subtle deficiencies in myogenesis 
such as reduced muscle specific genes, but no major defects in muscle development 
occurs, likely due to overlapping functions of other factors (Olson, Arnold, Rigby, & 
Wold, 1996). 
Myogenic Regulatory Factors 
Similar to the development of muscle during embryogenesis, muscle regeneration 
in response to injury is highly dependent on the proliferative response of satellite cells 
expressing myogenic regulatory factors (MRFs) to reconstruct functional myofibers. In 
adult muscle, SCs follow similar genetic programming exhibited in embryonic 
myogenesis, acting comparably to MPCs (Rudnicki, Le Grand, McKinnell, & Kuang, 
2008). When satellite cells become committed to myogenic fate, they express both Myf5 
and MyoD. In these active, proliferating myoblasts, early differentiation begins with the 
expression of myogenin, followed by Mrf4. Cells are now referred to as myocytes, which 
begin late differentiation, and form myotubes and ultimately fuse into myofibers (Figure 
2.2) (Bentzinger, Wang, & Rudnicki, 2012). During late differentiation, myocytes also 
express genes for muscle creatine kinase (MCK) and myosin heavy chain (MyHC), 
responsible for contractile structure (Karalaki, Fili, Philippou, & Koutsilieris, 2009). 
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Figure 2.2. Hierarchy of transcription factors regulating progression through the 
myogenic lineage (Bentzinger et al., 2012) 
 
Myogenic Factor 5 
Myogenic factor 5 (Myf5) is the earliest expressed MRF in skeletal myogenesis 
(Zweigerdt, Braun, & Arnold, 1997). Myf5, along with MyoD, is required for 
determination to myogenic lineage. Myf5 interacts with Pax3 upstream of MyoD and 
may be responsible for specifying muscle cell types (Tajbakhsh, Rocancourt, Cossu, & 
Buckingham, 1997). Pax7 indirectly up-regulates Myf5 expression, inducing myoblast 
proliferation (McKinnell et al., 2008). Decreased Myf5 expression early in myogenesis 
inhibits differentiation. Defects in Myf5 expression have been shown to decrease 
development of rib muscles and lead to perinatal or neonatal death, as evidenced by 
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Myf5-/- knockout mice (Braun et al., 1992). Myf5-null myoblasts have been shown to 
proliferate poorly and differentiate quickly (Montarras, Lindon, Pinset, & Domeyne, 
2000). A predominant Myf5 expression versus MyoD in adult muscle has been shown to 
direct greater myoblast proliferation and delayed differentiation, which may be 
responsible for satellite cell self-renewal (Figure 2.3) (Rudnicki et al., 2008).  
 
 
Figure 2.3. Satellite cell activation and differentiation in myogenesis and regeneration 
(Karalaki et al., 2009) 
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MyoD  
MyoD is often considered to be the master regulatory gene in the myogenesis 
process, due to its ability to modify numerous cell types (fibroblasts, chondrocytes, 
neural cells) into myoblasts (Choi et al., 1990). It was the first discovered of the MRF 
family. Failure to express MyoD early in development leads to reduced differentiation 
and growth of muscles (Megeney, Kablar, Garrett, Anderson, & Rudnicki, 1996). 
Cultured MyoD-null myoblasts grow quickly, but abnormally express target muscle 
promoter genes (i.e., MCK, MyHC) and differentiate poorly (Sabourin, Girgis-Gabardo, 
Seale, Asakura, & Rudnicki, 1999). When MyoD genes were deleted in mouse models, 
Myf5 overexpressed and compensated for MyoD; despite vitality, muscle developed 
abnormally and showed defects in regeneration (Martin, 2003). In spite of Myf5’s 
compensatory capacity, MyoD more effectively targets a greater number of genes 
inducing differentiation (Ishibashi, Perry, Asakura, & Rudnicki, 2005). Mice deficient in 
both MyoD and Myf5 fail to form skeletal muscle, and die at birth (Martin, 2003). MyoD 
mRNA has been shown to be more prevalent in fast glycolytic muscles and may play a 
role in fiber-type determination. Mice lacking functional MyoD genes shifted fiber type 
distribution and MyHC isoforms toward oxidative metabolism (Hughes, Koishi, 
Rudnicki, & Maggs, 1997). 
MyoD appears to be explicitly involved in DDR processes of skeletal muscle. In 
response to DNA damage, an ABL (Abelson murine leukemia) tyrosine kinase 
phosphorylates MyoD at tyrosine 30, arresting myoblasts at the G1/S checkpoint. MyoD 
is prevented from activating muscle gene expression for synthesis (Simonatto et al., 
2011). Rather than performing transcriptional activation of muscle synthesis, MyoD 
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recruits phosphorylated Nbs1 (Nijmegen breakage syndrome 1 gene) to target and repair 
damaged chromatin. Nbs1 binds to phosphorylated H2AX foci of DSB and begins DNA 
repair activities (Kobayashi et al., 2004). MyoD-null mice fail to repair DNA lesions, 
allowing for proper synthesis activities to occur (Simonatto et al., 2013). When DNA 
damage is detected at the G2/M phase checkpoint, MyoD cannot bind DNA sequences of 
target genes, and cell arrest is induced before mitosis occurs. 
Myogenin 
Myogenin is expressed at the entry into the terminal differentiation program, 
before fusion and differentiation of myoblasts to multinucleated myotubes (Smith, 
Janney, & Allen, 1994; Yutzey, Rhodes, & Konieczny, 1990). Knockout mouse models 
cause death at birth because myogenin-/- myoblasts are unable to fuse and form 
differentiated myofibers (Hasty et al., 1993; Rawls et al., 1998; Vivian, Olson, & Klein, 
2000). Muscle progenitors in these myogenin -/- mice still express MyoD and Myf5, but 
muscle differentiation is defective (Martin, 2003). Unlike MyoD, myogenin transcript 
mRNA has been found to be expressed greater in slow MyHC isoforms (Hughes et al., 
1993). Additionally, overexpression of myogenin results in greater oxidative metabolism, 
with a decrease in glycolytic enzyme concentration (Hughes, Chi, Lowry, & Gundersen, 
1999). Myogenin has been shown to increase following aerobic exercise in oxidative 
muscle, such as the SOL (Siu et al., 2004). 
Muscle Regulatory Factor 4 
Muscle regulatory factor 4 (Mrf4) is expressed lastly during terminal 
differentiation contributing to cell maturation, but also plays a role in the commitment of 
cell to muscle lineage. Like Myf5, Mrf4 acts upstream of MyoD in determining skeletal 
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muscle identity in the early somite (Kassar-Duchossoy et al., 2004). Inhibition of Mrf4 
results in reduced cell fusion and differentiation. Mrf4-/- models demonstrate severe 
muscle development deficiency. During early myogenesis, Mrf4 can act in place of 
myogenin and increase expression of Mrf4 genes and partial development of ribcage, but 
ultimately muscle development is defective and death occurs (Zhu & Miller, 1997). Mice 
deficient in both Mrf4 and MyoD display form similar to myogenin-null mice, with 
failure to differentiate myotubes (Rawls et al., 1998). Activities of Mrf4 are upregulated 
by MEF2/myogenin interaction, as well. Mrf4 is involved in the maintenance of muscle 
gene expression, and is present in mature myotubes. Expression of the other MRFs tend 
to decrease postnatally, but Mrf4 remains constant throughout the lifespan, as seen in 
mice (Bober et al., 1991; Hinterberger et al., 1991).  
 Myocyte Enhancer Factor 2 
The myocyte enhancer factor 2 (MEF2) group of proteins are members of MADS 
(MCM1, agamous, deficiens, serum response factor) box-containing family of 
transcription factors. MEF2 was discovered as a protein from skeletal muscle nuclei, 
which bound an A/T-rich sequence in muscle creatine kinase (MCK) gene promoters 
(Gossett, Kelvin, Sternberg, & Olson, 1989). Structurally, MEF2 proteins have an amino 
terminal composed of MEF and MADS boxes, which dimerize and bind DNA, and a 
carboxyl terminal, involved in gene activation and kinase response (Black & Olson, 
1998). 
In vertebrates, MEF2 proteins act as co-factors for transcription during muscle 
development. Evidence suggests MEF2 synergistically activates gene expression after the 
onset of differentiation, implicating their role in later stages of terminal differentiation 
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(Naya & Olson, 1999). In transgenic mice and cultured cells, MEF2 proteins bind to and 
are necessary for the expression of myogenin and Mrf4 (Olson et al., 1995; Weintraub, 
1993). Additionally, the myogenin and Mrf4 gene promoters do not have autoregulatory 
binding sites, but, in fact, have a site for the MEF2 protein, which enhances promoter 
activation (Edmondson, Cheng, Cserjesi, Chakraborty, & Olson, 1992; Naidu, Ludolph, 
To, Hinterberger, & Konieczny, 1995).  
MEF2C genes are expressed in several tissues, but first appear in the precardiac 
mesoderm. Targeted inactivation of MEF2C in embryonic mice leads to lethal defects in 
cardiac development (Lin, Schwarz, Bucana, & Olson, 1997). Throughout the mouse 
embryo, MEF2C is also expressed in smooth muscles. MEF2A, -B, and -D are expressed 
ubiquitously in various non-muscle cells (Lyons, Micales, Schwarz, Martin, & Olson, 
1995). A few hours after myogenin is expressed in skeletal muscle-bound cells, MEF2C 
becomes evident (Figure 2.4) (Edmondson et al., 1992). In adults, MEF2C expression is 
limited to skeletal muscle, brain, and spleen, but its roles are essential in the origins of 
cardiac and smooth muscle. 
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Figure 2.4. Sites of MEF2 proteins influence in myogenesis (Olson et al., 1995) 
 
Inhibitor of DNA Binding 
The inhibitor of DNA binding (Id) protein is an HLH (helix-loop-helix) structure 
that competitively binds to E-proteins. Id lacks the basic region for DNA binding seen in 
the bHLH family of MRFs. The binding affinity of Id is substantially greater than MRFs 
and acts as a negative regulator of the MRFs, sequestering potential of MRF dimer 
partners (Benezra, Davis, Lockshon, Turner, & Weintraub, 1990). In normal 
circumstances, Id is present and heterodimerizes with E-proteins, but the level expressed 
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is not adequate to bind all dimer partners. Remaining E-proteins are able to 
heterodimerize with MRFs and proceed in myoblast determination.  
Id is expressed in a number of proliferating cells and typically decreases 
expression upon induced differentiation (Biggs, Murphy, & Israel, 1992; Sun, Copeland, 
Jenkins, & Baltimore, 1991). When levels increase substantially, the overexpression of Id 
in myoblasts inhibit muscle differentiation (Üyashi et al., 1994). Additionally, Id proteins 
are overexpressed in a nuÜber of human cancers and elevated expression is correlated 
with higher histological grades (Ruzinova & Benezra, 2003). Other factors such as Twist, 
Mist1, MyoR, and Sharp-1 also inhibit MRF transcriptional activities, DNA-binding, and 
E-protein dimerization (Azmi, Ozog, & Taneja, 2004; Lemercier, To, Carrasco, & 
Konieczny, 1998; Lu, Webb, Richardson, & Olson, 1999; Spicer, Rhee, Cheung, & 
Lassar, 1996). 
Doxorubicin and Myogenic Regulatory Factors 
C2C12 myoblasts exposed to DOX in vitro down-regulate MyoD and myogenin 
gene transcripts, while increasing levels of Id (Kurabayashi et al., 1993, 1994). As Id 
competes for E-protein binding, elevated expression reduces availability for MRF 
heterodimerization and transcript signaling for myoblast determination (Puri et al., 1997).  
As previously mentioned, MyoD directly contributes to signaling of DNA repair 
when myoblasts are exposed to DNA-damaging agents (i.e., DOX). C2C12 myoblasts 
deficient in MyoD with inhibited ABL kinases exhibit impaired DNA repair activity 
when exposed to DOX compared to wild type (WT) controls. Removing ABL kinase 
inhibitors does not restore repair mechanisms, and requires functional MyoD to direct 
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phosphorylated Nbs1 to DNA-damaged foci on target genes, including myogenin 
promoter and muscle creatine kinase (MCK) enhancer (Simonatto et al., 2013). 
DOX arresting myoblasts at the G2/M phase does not allow MyoD to bind DNA 
and activate differentiation (Kurabayashi et al., 1994; Puri et al., 1997). DOX-induced 
arrest during the G2 phase reduces MyoD occupancy on myogenin and MCK target genes 
(Simonatto et al., 2011). Puri and collegues (1997) exposed C2C12 mouse myoblasts to 
DOX, ceasing the cell cycle at the same checkpoint, and demonstrated DNA synthesis 
occurred without apoptosis following removal from DOX. These researchers found DOX 
treatment led to an up-regulation in p21 proteins. p21 is a cyclin D kinase inhibitor, 
which regulates passage through the cell cycle checkpoints. It responds to p53 by 
mediating cell cycle arrest without inducing apoptosis. After exposure to DOX, p21 
expression positioned myotubes in a reversible arrested state (Puri et al., 1997). p53 
either directly signals apoptosis or p21 to arrest cells in a senescent state for DNA repair 
before restarting the cell cycle.  
Despite the shielded state of SCs to gentoxic stress while in a quiescent state, 
once activated for muscle regeneration, SCs become susceptible to DNA damage. SCs 
from MyoD-null mice exposed to DOX demonstrate DDR signaling; however, significant 
delay in response and incomplete DNA repair persists up to 48 hours following damage. 
Reintroduction of WT MyoD and ABL kinase restores repair ability and corrects DNA 
lesions in treated SCs (Simonatto et al., 2013).  
The reduced expression of myogenic markers, MyoD and Myf5, suggests a 
decrease in the determination of satellite cells to become new muscle cells. An elevation 
in Myf5 expression has been shown to proliferate myoblasts, with some reversing into a 
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quiescent, satellite state for later differentiation. The increased SC number may assist 
with muscle regeneration in the period following DOX treatment after its systemic 
removal. The reduced expression of markers, Mrf4 and myogenin, will decrease the 
ability of potential myocytes to differentiate into myotubes. The α-like RNA polymerase 
core II subunit 3 (RPB3) specifically binds to myogenin, and not the other MRFs (Corbi 
et al., 2002). DOX down-regulates RPB3 expression, which is correlated with inhibited 
muscle differentiation. Activation of myogenin, and subsequent muscle differentiation, 
may be blocked due to reduced RPB3 via DOX treatment (Martin, 2003). Exposure of 
C2C12 myoblasts to genotoxic agents, such as DOX, reduced myotube formation by 60-
75% and inhibited expression of myogenin and MyHC seen late in the myogenic process 
(Puri et al., 2002). Reduced levels of MyoD were not evident in this study, but E-box 
DNA binding by MyoD is dramatically reduced following DOX treatment in myocytes 
induced to differentiate (Puri et al., 1997). 
As far as reductions in one MRF versus another, fluctuations can potentially 
affect the muscle’s phenotype. In a normal, healthy state, oxidative (Type I) muscles 
express higher levels of myogenin, while fast, glycolytic (Type II) muscles express 
greater MyoD genes. Preserving myogenin in SOL and MyoD in EDL will presumably 
maintain the normal muscle status. With endurance TM training adaptations acting more 
upon oxidative muscles, increased/maintained muscle mass should be evident more so in 
these tissues.  
Exercise Preconditioning 
 Just as muscle can hypertrophy due to exercise and growth factors, significant 
decreases in muscle size can occur as result of injury, disease, denervation, cachexia, 
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prolonged disuse, sepsis, and oxidative stress (Tisdale, 2009). Aerobic exercise training 
interventions are preventative measures used in mitigating the negative effects associated 
with cancer treatments (Dimeo, Fetscher, Lange, Mertelsmann, & Keul, 1997; Dimeo, 
Rumberger, & Keul, 1998; Chicco, Hydock, Schneider, & Hayward, 2006). Although 
acute exercise increases free radical generation and tissue damage, repetitive training 
appears to enhance antioxidant enzymes and oxidative repair systems (Gomez-Cabrera, 
Domenech, Ji, & Viña, 2006; Radak, Chung, & Goto, 2008; Radak, Chung, Koltai, 
Taylor, & Goto, 2008).  
The effect of DOX generating uncontrollable ROS has been shown to decrease 
skeletal muscle mass and fatigue resistance. Increases in ROS scavenging antioxidants 
and attenuated functional deficits due to chronic aerobic exercise regimens prior to DOX 
administration are widely reported (Ascensão et al., 2012; Chicco, Hydock, Schneider, & 
Hayward, 2006; Chicco, Schneider, et al., 2006; Hydock et al., 2011b; Kanter, Hamlin, 
Unverferth, Davis, & Merola, 1985; Wonders, Hydock, Schneider, & Hayward, 2008). 
Short-term exercise protocols prior to DOX treatment have been shown to protect cardiac 
and skeletal muscle function and elevate antioxidant enzymes, as well (Gomez-Cabrera, 
Domenech, & Viña, 2008; Kavazis et al., 2014). Furthermore, acute aerobic exercise 
attenuates myofibrillar degradation of actin in skeletal muscle and prevents increases in 
apoptotic signaling following DOX i.p. injections (Smuder, Kavazis, Min, & Powers, 
2011a; Smuder et al., 2011b). Even single bouts of endurance exercise have been shown 
to reduce lipid peroxidation seen in myocardial tissues following DOX injections 
(Wonders, Hydock, Schneider, & Hayward, 2008). 
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 As previously mentioned, Mrf4 is expressed at higher levels in adult muscles than 
the other MRFs. Innervation is thought to alter the expression of these proteins, with 
higher levels expressed following physical activity. Interestingly, with muscle 
denervation, Myf5 and MyoD mRNA levels increase at least two-fold, whereas 
myogenin transcript levels are elevated dramatically (Neville, Schmidt, & Schmidt, 1992; 
Voytik, Przyborski, Badylak, & Konieczny, 1993). When re-innervated, however, 
transcript levels rapidly return to basal conditions, without altering Mrf4 expression. 
Mice subjected to immobilization (muscle disuse) had increased levels of myogenin 
mRNA in the fast-twitch plantaris muscle while in lengthened positions. Shortened 
positions decreased muscle mass and Mrf4 mRNA levels in the slow-twitch soleus (SOL) 
muscle (Loughna & Brownson, 1996). Despite increases of mRNA following denervation 
and immobilization, functional protein expression has not shown similar effects. 
Effective protein expression appears to actually influence muscle mass versus mRNA, 
with the exception of Mrf4 in the shortened position of the SOL muscle.  
 Neuromuscular activity, such as exercise, may influence functional MRF protein 
expression in a more substantive manner. Siu and collegues (2004) found 24% greater 
myogenin protein expression in rats following 8 weeks of treadmill (TM) training than 
that of controls. Furthermore, oxidative metabolic enzyme levels and activity (i.e., citrate 
synthase, cytochrome-c oxidases) exhibited linear increases, which may assist in handling 
of ROS. As myogenin is a secondary MRF, its expression may be more readily examined 
following acute exercise training. With single bouts of resistance exercise in humans, 
MRF mRNA expression increases, but returns to basal levels within 24 hours (Psilander, 
Damsgaard, & Pilegaard, 2003; Yang, Creer, Jemiolo, & Trappe, 2005). Haddad and 
	 34 
	
Adams (2002) found greater myogenin transcript levels in rats with repeated bouts of 
exercise. Repeated endurance exercise bouts may elicit similar elevations in functional 
MRF protein levels. MRF transcript levels are found to decay 72 hours following 
exercise bouts (Bickel et al., 2005). Kosek and colleagues (2006) investigated responses 
to acute and chronic resistance training in humans. Following a single bout, no significant 
changes occurred in protein expression, whereas mRNA increased in myogenin alone. 
Following sixteen weeks of training, transcript levels of Myf5, MyoD, and myogenin 
were increased from baseline. Protein levels Mrf4 and myogenin were significantly 
higher after chronic resistance exercise (Kosek et al., 2006). No intermediate 
measurements were recorded to distinguish transitions from MRF mRNA to protein 
synthesis. Potential elevations of Myf5 and MyoD proteins may return to basal levels 
after chronic training, which might be revealed following short-term exercise training. 
 MyoD has been implicated as a key regulator of myogenic transcription, due to its 
association with ABL tyrosine kinase and ability to destabilize the non-functional DNA-
TOP2 complex. If levels of MyoD are up-regulated/maintained with short-term exercise 
training, muscle regeneration may be more viable following DOX treatment. Siu and 
collegues (2004) did not observe significant MyoD increases in SOL muscles following a 
TM protocol, but had the EDL been examined, levels may have been elevated due to 
fiber type and MRF expression patterns (Hughes et al., 1997; Hughes et al., 1993; Siu et 
al., 2004). 
Conclusion 
 Skeletal muscle cells’ ability to regenerate is impaired following exposure to 
DOX. p53-dependent apoptotic programs inhibit mitotic divisions and differentiation of 
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new myocytes. Additionally, DOX produces DNA lesions and prevents repair due to its 
inhibition of TOP2 function. Impaired ability to counter DNA damage in skeletal muscle 
could lead to accumulated lesions and loss of muscle integrity over time. Chronically 
elevated ROS production in skeletal muscle leads to proteolysis and cell death (Ji, 
Gomez-Cabrera, & Vina, 2006).  
 Aerobic exercise enhances ROS handling in skeletal muscle and lessens cellular 
damage attributed to oxidative stress. Additionally, aerobic training regimens will 
theoretically maintain the expression of MyoD and other MRFs, increasing the ability to 
maintain skeletal muscle DNA integrity following acute DOX treatment. DOX treatment 
elevates Id protein expression and decreases muscle force production ex vivo. 
Preconditioning, however, should potentially attenuate these DOX-induced dysfunctions 
in skeletal muscle.  
 Much of the existing literature focuses on in vitro myoblast exposure to DOX. An 
in vivo investigation may elucidate dynamic responses of muscle regeneration and 
functional MRF expression with prior aerobic conditioning. This study potentially 
demonstrated the therapeutic advantage of a short-term aerobic exercise intervention 
before DOX treatment to preserve skeletal muscle and future developmental capacity. 
Given the overlapping behaviors of MRFs, preservation of one or all should enhance 
muscle regenerative capacity, or temper muscle loss, and attenuate functional reductions 
following DOX treatment. 
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CHAPTER III 
METHODOLOGY 
Experimental Design 
Ten-week-old male Sprague Dawley rats (N=47) were randomly assigned to 
either treadmill training (EXER, n=27) or sedentary (SED, n=20) groups. After 2 weeks 
of endurance training, animals were randomly assigned to receive either a DOX or 
placebo injection. Animals received either 15 mg/kg DOX or saline (SAL) injection 
(Figure 3.1). Skeletal muscle function was measured ex vivo 24 hours post DOX/SAL 
injections. A lipid peroxidation assay was used to determine levels of oxidative stress. 
Western blot analysis was used to quantify the myogenic regulatory factor proteins, 
Myf5, MyoD, myogenin and Mrf4, in SOL and EDL. 
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Figure 3.1. Experimental Design for Treatments 
 
Animals and Animal Care 
All experimental procedures were approved by the University of Northern 
Colorado Institutional Animal Care and Use Committee (Protocol #1407C-DH-R-17) and 
were in compliance with the Animal Welfare Act guidelines (see Appendix A). Male 
Sprague Dawley rats (10-week old) were purchased from Harlan (Indianapolis, IN). All 
rats were housed in pairs under a 12:12 light-dark cycle at room temperature (20 ± 2°C), 
47	Rats
Sedentary	Group	(n=20)
2	Weeks	No	Training
15	mg/kg	DOX	Injection
SED-DOX(n=10)
Sacrifice	after	24	hrs
SAL	Injection
SED-SAL	(n=10)
Sacrifice	after	24	hrs
Exercise	Group	(n=27)
2	Weeks	Treadmill	Training
15	mg/kg	DOX	Injection
TM-DOX	(n=14)
Sacrifice	after	24	hrs
SAL	Injection
TM-SAL	(n=13)
Sacrifice	after	24	hrs
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and food (Harlan Teklad 2016 rodent chow) and water was provided ad libitum. Rats 
were randomly assigned to one of four groups: (1) SED-SAL (Sedentary, Saline; n=10), 
(2) SED-DOX (Sedentary, DOX; n=10) (3) EXER-SAL (Exercise, Saline; n=13) and (4) 
EXER-DOX (Exercise, DOX; n=14). Body mass (g) for each animal was obtained at the 
start and end of training and before sacrifice. 
Exercise Training Protocol 
Animals assigned to exercise preconditioning groups trained for 2 weeks on a 
motorized treadmill during their dark cycle. In week 1, animals began running on a 
treadmill for 10 minutes and duration was increased 10 minutes each day. During week 2, 
animals trained for 60 minutes total per session (see Table 3.1). Speed remained constant 
at 30 meters per minute. The treadmill work rate used represents an estimated 70% of 
VO2max (Lawler, Powers, Hammeren, & Martin, 1993). When necessary, rats were 
motivated by light electric shock at the rear of treadmill lanes. An exercise regimen of 
similar conditions provoked significantly less ROS generation in rats that trained on 
treadmills compared to sedentary animals (Smuder et al., 2011b). Furthermore, human 
experiments demonstrated the need for more than one exercise bout to prompt myogenin-
positive stained satellite cells, and thus, differentiating myoblasts (Raue, Slivka, Jemiolo, 
Hollon, & Trappe, 2006). All animals assigned to EXER completed training protocols. 
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Table 3.1 
Treadmill exercise training protocol 
Day 1 2 3 4 5 6 – 7  8 - 12 
Speed (m/min) 30 30 30 30 30 (Rest) 30 
Duration (min) 10 20 30 40 50 (Rest) 60 
Incline (%) 0 0 0 0 0 (Rest) 0 
 
Drug Treatment 
To eliminate acute effects of exercise, animals received injections 24 hours after 
the completion of the last treadmill training session. One half of both sedentary (10) and 
exercise (14) trained groups were randomly assigned to receive DOX hydrochloride 
(Bedford Labs: Bedford, OH) injections. The remaining animals (23) received 0.9% 
saline placebo. A bolus injection of 15 mg/kg DOX was delivered intraperitonally (i.p) 
on the right side of the abdominal cavity. Control animals received an equivalent volume 
of saline. Twenty-four hours after injections, rats were sacrificed and tissues extracted. 
The period between exercise and injection allowed sufficient time for MRF protein 
synthesis. Additionally, the twenty-four hour time period minimized effects due to 
anorexia-associated catabolism following treatment. Animals treated with DOX 
significantly reduce food and water intake within 24 hours to several days (Gilliam et al., 
2009). Muscle masses should not be significantly affected in this 1-day period.  
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Isolated Muscle Function 
Tissue Preparation 
Animals were acutely anesthetized with sodium pentobarbital (50 mg/kg). After 
animals were completely anesthetized, indicated by failure to respond to a tail pinch, the 
soleus (SOL) and extensor digitorum longus (EDL) were be quickly excised from the 
right hindlimb and transferred to a tissue bath of Krebs Henseleit buffer (120 NaCl, 5.9 
KCl, 2.5 CaCl2, 1.2 MgCl, 25 NaHCO3, 17 glucose; in mM) for muscle function data 
collection. Animals were sacrificed prior to recovery from anesthesia by removal of the 
heart. Contralateral muscles were also be removed, trimmed free of connective tissue and 
fat, blotted dry, weighed, flash frozen in liquid nitrogen and stored at -80°C for later 
biochemical analysis.  
The SOL and EDL muscles were chosen for examination to give a representation 
of two different muscle types (Type I: SOL; Type 2: EDL). Muscles were removed 1 day 
following the end of training because oxidative enzymes are not affected more than 48 
hours after acute endurance exercise training (Siu, Donley, Bryner, & Alway, 2003). In 
young humans, MRF mRNA levels peak 12 hours after exercise (Williamson, Godard, 
Porter, Costill, & Trappe, 2000). mRNA transcripts, however, are not functional proteins. 
In fact, MRF mRNA can be upregulated without activation of SCs (Lowe & Alway, 
1999). MyoD and myogenin have been shown in myonuclei as early as 1 day post 
functional overload in rodent models (Ishido, Kami, & Masuhara, 2004).  
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Ex Vivo Muscle Function 
Functional muscle data were obtained via electrostimulation of tissues in organ 
baths (Radnoti: Monrovia, CA). Two electrodes surrounding the muscle in organ baths 
provided stimulation. Muscle contraction forces were recorded using PowerLab data 
acquisition hardware (ADInstruments: Colorado Springs, CO). Maximal twitch force was 
achieved by adjusting muscle for optimal length, and subsequent change in voltage 
applied (Grass Technologies: Warwick, RI).  
The muscle stimulation methods follows the protocol reported by Hydock et al. 
(2011). Muscles were allowed to stabilize in the warmed (37°C) and oxygenated (95% 
O2/5% CO2) organ bath prior to functional data collection. Initial muscle tension was 
adjusted to 0.5 g, and stimulated with a square-wave pulse duration of 0.5 ms at 40 V. 
Muscle tension was increased by 0.2 g per stimulation (2-minute rest) until twitch force 
reaches a maximum. Next optimal voltage was verified by increasing applied voltage by 
increments of 5 V, allowing the same 2-minute rest period. Once maximal twitch force 
was determined, the bath of Krebs-Henseleit buffer was be cycled for a new volume to 
ensure proper electrolyte balance for ensuing fatigue resistance recording. The muscle 
was allowed a recovery time of 30 minutes in fresh buffer before continuous stimulation 
cycling. Pulse duration was increased to 500 ms while maintaining the determined 
optimal length and voltage. The muscle was stimulated continuously every 1 second for 2 
minutes to simulate fatiguing conditions (Hydock, Lien, Jensen, Schneider, & Hayward, 
2011a). LabChart software (ADInstruments) was used to analyze force data acquired. 
Measures of maximal force, maximal rate of force development, and maximal rate 
of force decline were recorded during the single twitch force stimulation recordings. 
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During the continuous, fatiguing protocol, force production were recorded in reference to 
baseline levels every 10 seconds, for a total of 100 seconds.   
Biochemical Analyses 
Homogenate Preparation 
The flash frozen left hindlimb muscles were homogenized in 
radioimmunoprecipitation assay (RIPA) buffer (10:1) and protease enzyme inhibitors 
(SigmaAldrich: St. Louis, MO). After manual homogenization, samples were sonicated to 
increase nuclear protein recovery. Homogenates were then be spun in a microcentrifuge 
for 10 minutes at 3000 g at 4°C. Total protein was quantified in samples using a Genesys 
20 photospectrometer (ThermoSpectronic: Rochester, NY) at 562 nm according to the 
bicinchronic acid (BCA) assay (Smith et al., 1985). A determined amount of RIPA buffer 
was added to standardize protein concentration. 
Lipid Peroxidation 
The most abundant product of LPO is malondialdehyde (MDA), and it is 
commonly assayed as an index of oxidative stress. LPO was determined using a 
commercially available assay kit (BioxyTech MDA-586, Oxis Research: Foster City, 
CA). Malondialdehyde and 4-hydroxyalkenals (MDA+4-HAE) were measured to 
indicate cellular lipid peroxidation. 200 µL of sample homogenates were added to a 
microcentrifuge tube. 650 µL of N-methyl-2-phenylindole in acetonitrile was added to 
the sample and briefly vortexed. 150 µL of methanesulfonic acid was then be added and 
vortexed, followed by a 60 minute incubation period at 45°C. Following the incubation 
period, samples were centrifuged at 10,000 g for 10 minutes to remove turbidity. 
Supernatants were then transferred to cuvettes for absorbency measurement using a 
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spectrophotometer at 586 nm. Concentration of MDA+4-HAE was estimated from a 
standard curve. Samples were run in duplicate, with reassay if samples vary by more than 
5%. 
Western Blotting 
Western blot analysis was conducted on muscle samples for the presence of 
MRFs in the SOL and EDL via SDS-PAGE. An equal volume of Lammeli buffer was 
added to samples in a microcentrifuge polypropylene vial, reducing protein concentration 
in half. Samples were heated in boiling water for 2 minutes, then chilled on ice for 5 
minutes before 46 µg was loaded onto 4-20% gradient Tris-Glycine NuPage precast gels 
(LifeTechnologies: Carlsbad, CA). Gels were run at 125 V (constant voltage) and 4 mA 
current for 2 hours in a Xcell II blot module (Invitrogen, LifeTechnologies), until 
proteins had migrated the whole gel. Proteins were transferred to 0.45 micron 
polyvinylidene fluoride (PVDF) membranes over 90 minutes at 25 V and 100 mA. 
Protein transfers to PVDF membranes were ensured by the presence of a SeeBlue® Plus2 
protein ladder (Novex, LifeTechnologies). Membranes were blocked for 1 hour in 15 mL 
of TBST + 5% milk, and then incubated with gentle agitation overnight in 10 mL of 
primary antibodies. Membranes were then be washed in TBST three times for 5 minutes, 
followed by incubation in appropriate species-specific secondary antibodies for 1 hour. 
After three more 5-minute washes in TBST, membranes were prepared for protein band 
detection.  
Detection was executed by enhanced chemiluminescence (ECL) (C-Digit, Li-Cor: 
Lincoln, NE), and ImagJ software (NIH: Bethesda, MD) was used to quantify protein 
expression. Immediately before chemiluminescent imaging, 1.5 mL of luminol and 
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enhancer (SuperSignal West Femto Maximum Sensitivity Chemiluminescent Substrate, 
ThermoScientific: Waltham, MA) was added to the membrane. The primary antibodies of 
interest included rabbit monoclonal MyoD and myogenin (Santa Cruz Biotechnology: 
Dallas, TX) and Myf5 and Mrf4 (Abcam: Cambridge, MA). The rabbit monoclonal anti-
GAPDH (Abcam) was used as a loading control. Molecular weights of protein bands 
were ensured in reference to a MagicMark™ XP standard ladder (Novex, 
LifeTechnologies). Secondary antibodies (Santa Cruz Biotechnology) corresponded to 
associated species (rabbit) and include horseradish peroxidase (HRP) for adequate 
reactivity. 
Statistical Analysis 
Data were analyzed using GraphPad Prism statistical software (GraphPad: 
LaJolla, CA) and presented as means ± standard error (mean±SEM). A two-factor 
(Exercise X Drug) analysis of variance (ANOVA) was used to determine main effects 
and interactions of treatments in muscle mass, muscle force production, lipid 
peroxidation, and MRF concentration. If a significant F-value was observed, a Tukey 
post-hoc pair-wise comparison identified significant differences between groups. 
Variables included the four MRF proteins concentrations, muscle masses, and force 
parameters from ex vivo analysis in each of the groups (maximal twitch, maximal rate of 
force production, and maximal rate of force decline). Muscle fatigue responses were 
analyzed with maximal twitch force obtained every 10 seconds and compared to baseline 
measures. For this study, muscle fatigue was defined at the point at which force 
production was below 75% of baseline skeletal muscle twitch force. For statistical 
procedures, significance was set at the α=0.05 level. 
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CHAPTER IV 
RESULTS 
 The purpose of this study was to determine the effects of acute DOX 
administration on skeletal muscle force production and fatigue resistance, lipid 
peroxidation (LPO), and MRF expression in skeletal muscles.  Additionally, this study 
investigated the effects of short-term endurance exercise training on muscle force 
production and fatigue resistance, LPO, and MRF expression. This chapter presents 
findings of the study. 
General Observations 
Table 4.1 presents animal characteristics at the time of injection after training and 
at the time of sacrifice. At the time of injection, animal body mass was significantly 
different between groups. An activity effect was observed with SED animals exhibiting 
significantly greater body mass, F (1, 43) = 16.72, p<0.05. Post hoc testing revealed body 
mass to be higher in SED-SAL and SED-DOX than EXER-SAL, p<0.05. 
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Table 4.1  
Animal Characteristics. 
 SED-SAL SED-DOX EXER-SAL EXER-DOX 
Injection Body Mass (g)  360 ± 11 a 364 ± 10 a   322 ± 5   335 ± 7 
Sacrifice Body Mass (g)  360 ± 12 b 354 ± 9 b   326 ± 6   329 ± 6 
SOL Mass (mg) 135 ± 7 140 ± 4   132 ± 5   133 ± 5 
EDL Mass (mg) 142 ± 5 138 ± 8   135 ± 4   141 ± 4 
SED-SAL = sedentary saline, n=10; SED-DOX = sedentary doxorubicin, n=10; EXER-
SAL = exercise saline, n=13; EXER-DOX = exercise doxorubicin, n=14. Values are 
means ± SEM. 
a = Significantly greater than EXER-SAL (p<0.05). 
b = Significantly greater than EXER-DOX (p<0.05). 
Significant activity effect in injection and sacrifice body mass (p<0.05). 
 
At the time of sacrifice, a similar activity effect existed with greater mass in SED 
animals, F (1, 43) = 13.42, p<0.05. Post hoc testing revealed that EXER-DOX body mass 
was significantly less than SED-SAL and SED-DOX, p<0.05. A significant drug effect 
was observed in body mass change, as well, F (1.43) = 34.65, p<0.05 (Figure 4.1). Rats 
receiving SAL slightly gained body mass after injections (1%) while those receiving 
DOX decreased body mass (2.5%). Within groups, body mass changes were not 
significantly different (p>0.05).  
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Figure 4.1. Change in body mass following injections.  
SED-SAL = sedentary saline, n=10; SED-DOX = sedentary doxorubicin, n=10; EXER-
SAL = exercise saline, n=13; EXER-DOX = exercise doxorubicin, n=14. Values are 
mean ± SEM. 
a = Significantly different from EXER-SAL (p<0.05). 
b = Significantly different from SED-SAL (p<0.05). 
Significant drug effect (p<0.05). 
 
 There was no significant difference in absolute SOL mass observed between 
groups, p>0.05 (Figure 4.2A). Similarly, when SOL mass was corrected for body mass, 
no significant difference was detected, p>0.05 (Table 4.2, Figure 4.3A). Absolute EDL 
masses displayed no significant differences for main effects or exercise by drug 
interaction, p>0.05 (Figure 4.2B). When corrected for body mass, an activity effect was 
detected with endurance-trained animals demonstrating higher relative EDL mass, F = (1, 
43) = 4.871, p<0.05 (Figure 4.3B).  
 
SE
D-
SA
L
SE
D-
DO
X
EX
ER
-S
AL
EX
ER
-D
OX
-15
-10
-5
0
5
10
B
od
y 
M
as
s 
C
ha
ng
e 
(g
)
ab
ab
	 48 
	
 
Figure 4.2. Tissue mass at time of sacrifice, SOL (A) and EDL (B).  
SOL = soleus, EDL = extensor digitorum longus, SED-SAL = sedentary saline, n=10; 
SED-DOX = sedentary doxorubicin, n=10; EXER-SAL = exercise saline, n=13; EXER-
DOX = exercise doxorubicin, n=14. Values are mean ± SEM. 
 
Table 4.2 
Tissue mass relative to body mass. 
  SED-SAL  SED-DOX EXER-SAL EXER-DOX 
SOL (mg/g BM) 0.37 ± 0.01 0.39 ± 0.01  0.40 ± 0.01 0.41 ± 0.01 
EDL (mg/g BM) 0.39 ± 0.01 0.39 ± 0.02  0.42 ± 0.01 0.43 ± 0.01 
SOL = soleus, EDL = extensor digitorum longus, SED-SAL = sedentary saline, n=10; 
SED-DOX = sedentary doxorubicin, n=10; EXER-SAL = exercise saline, n=13; EXER-
DOX = exercise doxorubicin, n=14. Values are mean ± SEM. 
Significant activity effect in EDL (p<0.05). 
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Figure 4.3. Tissue mass relative to body mass, SOL (A) and EDL (B). 
SOL = soleus, EDL = extensor digitorum longus, BM = body mass, SED-SAL = 
sedentary saline, n=10; SED-DOX = sedentary doxorubicin, n=10; EXER-SAL = 
exercise saline, n=13; EXER-DOX = exercise doxorubicin, n=14. Values are mean ± 
SEM. 
Significant activity effect in EDL (p<0.05). 
Isolated Muscle Function 
Maximal Twitch Force 
Once right SOL and EDL were excised, muscles were placed in organ baths filled 
with Krebs-Henseleit buffer. Tension and voltage were gradually increased to determine 
optimum conditions as detected by maximal twitch force elicited. Additionally, rate of 
force production and rate of force decline were measured from maximal twitch force 
tracings. 
No significant differences were observed in SOL maximal twitch forces between 
groups, p>0.05 (Table 4.3). After adjusting force relative to tissue mass, significance 
remained undetected (Figure 4.4).  Rates of force production and decline were also not 
significantly different between groups, p>0.05.  
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Table 4.3 
SOL muscle twitch forces 
       SED-SAL      SED-DOX    EXER-SAL   EXER-DOX 
Maximal Twitch 
Force (mN) 
        37 ± 3        50 ± 5        44 ± 4       46 ± 4 
Relative Maximal 
Twitch Force 
(mN/g) 
      249 ± 36      287 ± 29      258 ± 28     296 ± 41 
Maximal Rate of 
Force Production 
(mN/s) 
    4916 ± 463    6376 ± 699    5478 ± 670   5536 ± 589 
Maximal Rate of 
Force Decline 
(mN/s) 
  - 1715 ± 193  - 1935 ± 160  - 2027 ± 117 - 2255 ± 154 
 
SOL = soleus, SED-SAL = sedentary saline, n=10; SED-DOX = sedentary doxorubicin, 
n=10; EXER-SAL = exercise saline, n=13; EXER-DOX = exercise doxorubicin, n=14. 
Values are mean ± SEM. 
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Figure 4.4. SOL Maximal twitch force values. Maximal twitch (A), maximal twitch 
relative to tissue mass (B), rate of force production (C), rate of force production (D), SOL 
rate of force decline. 
SOL = soleus, SED-SAL = sedentary saline, n=10; SED-DOX = sedentary doxorubicin, 
n=10; EXER-SAL = exercise saline, n=13; EXER-DOX = exercise doxorubicin, n=14. 
Values are mean ± SEM. 
 
No significant differences were seen between groups in EDL maximal twitch 
forces, p>0.05 (Table 4.4). Similarly, no significance was observed after correcting for 
tissue mass. Rates of force production and decline were not significantly different 
between groups, as well (Figure 4.5). 
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Table 4.4 
EDL muscle twitch forces 
      SED-SAL       SED-DOX     EXER-SAL   EXER-DOX 
Maximal Twitch 
Force (mN) 
       79 ± 7         90 ± 9         92 ± 8      77  ± 12 
Relative Maximal 
Twitch Force 
(mN/g) 
     511 ± 26       603 ± 69       632 ± 51     545 ± 80 
Maximal Rate of 
Force Production 
(mN/s) 
 14407 ± 1199   17851 ± 2060   18242 ± 1772 14966 ± 2603 
Maximal Rate of 
Force Decline 
(mN/s) 
- 8489 ± 690 - 10410 ± 1155 - 11583 ± 1272 - 9308 ± 1380 
EDL = extensor digitorum longus, SED-SAL = sedentary saline, n=10; SED-DOX = 
sedentary doxorubicin, n=10; EXER-SAL = exercise saline, n=13; EXER-DOX = 
exercise doxorubicin, n=14. Values are mean ± SEM. 
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Figure 4.5. EDL Maximal twitch force values. Maximal twitch (A), maximal twitch 
relative to tissue mass (B), rate of force production (C), rate of force production (D), SOL 
rate of force decline. 
EDL = extensor digitorum longus, SED-SAL = sedentary saline, n=10; SED-DOX = 
sedentary doxorubicin, n=10; EXER-SAL = exercise saline, n=13; EXER-DOX = 
exercise doxorubicin, n=14. Values are mean ± SEM. 
 
Fatigue 
After cycling Krebs-Henseleit buffer and allowing muscles to rest for 30 minutes, 
a 2-minute continuous stimulation at determined optimal length and voltage was 
performed. Time-to-fatigue was determined when muscles produced 75% of baseline 
force production. 
 In the SOL, SED-DOX and EXER-SAL generated less than 75% baseline force 
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production was below 75%. SED-SAL recorded the greatest fatigue resistance with 
twitch forces lower than 75% of baseline by 70 seconds (Figure 4.6). 
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Figure 4.6. SOL fatigue resistance.  
SOL = soleus, SED-SAL = sedentary saline, n=10; SED-DOX = sedentary doxorubicin, 
n=10; EXER-SAL = exercise saline, n=13; EXER-DOX = exercise doxorubicin, n=14. 
Values are means ± SEM. 
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In the EDL, SED-SAL fatigued quickest with twitch forces less than 75% at the 
40-second time point. SED-DOX, EXER-SAL, and EXER-DOX groups’ forces fell 
below fatigue threshold at 50 seconds (Figure 4.7). The fast-twitch muscle typically 
fatigues a greater rate than slow, oxidative muscles. Ex vivo force production of the EDL 
did not fatigue faster to levels below 75% of initial force values but, at the end 100 
seconds, all forces were below those of SOL. 
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Figure 4.7. EDL fatigue resistance. 
EDL = extensor digitorum longus, SED-SAL = sedentary saline, n=10; SED-DOX = 
sedentary doxorubicin, n=10; EXER-SAL = exercise saline, n=13; EXER-DOX = 
exercise doxorubicin, n=14. Values are means ± SEM 
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Biochemical Analyses 
Lipid Peroxidation 
SOL and EDL homogenates obtained from rats 1 day after saline or DOX 
injection were analyzed for markers of lipid peroxidation (MDA+4-HAE). All data from 
LPO analysis are presented in Table 4.5. In SOL, a significant drug effect was observed 
in rats receiving SAL exhibited higher levels of MDA+4-HAE, F = (1, 43), p<0.05 
(Figure 4.8A). EXER-SAL animals presented significantly greater indices of lipid 
peroxidation than SED-DOX and EXER-DOX. No activity effect or interaction was 
detected in the SOL. In the EDL, a significant activity effect was observed with TM 
animals presenting higher MDA+4-HAE, F = (1, 43) = 4.08, p<0.05 (Figure 4.8B). No 
drug effect or interaction was detected. 
 
Table 4.5 
Lipid peroxidation levels 
 SED-SAL SED-DOX EXER-SAL EXER-DOX 
SOL (pmol/mg)  329 ± 24 275 ± 17 a   398 ± 36   292 ± 17 a 
EDL (pmol/mg)  214 ± 14 225 ± 17   283 ± 28   288 ± 44 
SOL = soleus, EDL = extensor digitorum longus, SED-SAL = sedentary saline, n=10; 
SED-DOX = sedentary doxorubicin, n=10; EXER-SAL = exercise saline, n=13; EXER-
DOX = exercise doxorubicin, n=14. Values are mean ± SEM. 
a = Significantly different from EXER-SAL (p<0.05). 
Significant drug effect in SOL. 
Significant activity effect in EDL. 
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Figure 4.8. Lipid peroxidation levels in hindlimb muscles, SOL (A) and EDL (B). 
SOL = soleus, EDL = extensor digitorum longus, SED-SAL = sedentary saline, n=10; 
SED-DOX = sedentary doxorubicin, n=10; EXER-SAL = exercise saline, n=13; EXER-
DOX = exercise doxorubicin, n=14. Values are mean ± SEM. 
a = Significantly different from EXER-SAL. 
Significant drug effect in SOL (p=0.0033). 
Significant activity effect in EDL (p<0.05). 
 
Western Blotting 
Expression of myogenic regulatory factor proteins, Myf5, MyoD, Mrf4, and 
myogenin, were measured in SOL and EDL homogenates to evaluate the influence of 
endurance exercise and DOX on these transcription factors. Forty-six µg of protein from 
SOL and EDL homogenates were added to 4-20% Tris-glycine precast gels and run 
through SDS-PAGE. MRF levels were assessed by chemiluminescence and expressed 
relative to GAPDH as a loading control. It should be noted that no significant GAPDH 
activity of drug main effects or interactions (p>0.05) were observed suggesting that the 
exercise or drug treatments did not affect the loading control. All Western blot data are 
presented in Tables 4.6 (SOL) and 4.7 (EDL). 
 
 
 
 
SE
D
EX
ER
0
100
200
300
400
500
M
D
A
+4
H
A
E 
(p
m
ol
/m
g)
aa
A
SE
D
EX
ER
0
100
200
300
400
500
M
D
A
+4
H
A
E 
(p
m
ol
/m
g) SAL
DOX
B
	 60 
	
Table 4.6 
SOL Myogenic Regulatory Factor (MRF) levels 
  SED-SAL  SED-DOX EXER-SAL EXER-DOX 
Myogenic Factor 5 
(Myf5)  
0.44 ± 0.10 a 0.73 ± 0.14 0.92 ± 0.08 1.28 ± 0.22 
MyoD 1.29 ± 0.13 1.67 ± 0.13 1.46 ± 0.16 2.11 ± 0.31 
Myogenin 0.50 ± 0.12 0.67 ± 0.14 0.81 ± 0.17 0.80 ± 0.16 
Muscle Regulatory 
Factor 4 (Mrf4) 
0.62 ± 0.18 0.80 ± 0.20 1.23 ± 0.18 1.22 ± 0.24 
SOL = soleus, SED-SAL = sedentary saline, n=10; SED-DOX = sedentary doxorubicin, 
n=10; EXER-SAL = exercise saline, n=13; EXER-DOX = exercise doxorubicin, n=14. 
Values are mean ± SEM. 
a = Significantly different from EXER-DOX (p<0.05). 
Significant activity and drug effect in Myf5 (p<0.05). 
Significant drug effect in MyoD (p<0.05). 
Significant activity effect in Mrf4 (p<0.05). 
 
 
Table 4.7 
EDL Myogenic Regulatory Factor (MRF) levels 
  SED-SAL  SED-DOX EXER-SAL EXER-DOX 
Myogenic Factor 5 
(Myf5)  
1.25 ± 0.23 1.25 ± 0.19 1.57 ± 0.19 1.49 ± 0.14 
MyoD 1.28 ± 0.20 1.55 ± 0.17 1.30 ± 0.07 1.13 ± 0.09 
Myogenin 0.48 ± 0.15 0.64 ± 0.15 0.62 ± 0.11 0.67 ± 0.14 
Muscle Regulatory 
Factor 4 (Mrf4) 
0.47 ± 0.12 0.52 ± 0.13 0.64 ± 0.09 0.46 ± 0.08 
EDL = extensor digitorum longus, SED-SAL = sedentary saline, n=10; SED-DOX = 
sedentary doxorubicin, n=10; EXER-SAL = exercise saline, n=13; EXER-DOX = 
exercise doxorubicin, n=14. Values are mean ± SEM. 
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Myogenic Factor 5 
In the SOL, a 2-way ANOVA revealed a significant activity effect, with EXER 
groups exhibiting higher levels of myogenic factor 5 (Myf5), F (1, 43) = 10.42, p<0.05 
(Figure 4.9A). Additionally, a drug effect was observed, with DOX-treated groups 
expressing higher Myf5, F (1, 43) = 4.267, p<0.05. No significant interaction was 
observed. Post hoc tests revealed that SED-SAL expressed significantly less Myf5 than 
EXER-DOX. In the EDL, no significant main effects were observed, and no interaction 
was detected (Figure 4.9B).  
 
 
             
Figure 4.9. Myf5 expression levels, SOL (A) and EDL (B). 
SOL = soleus, EDL = extensor digitorum longus, OD = optical density, SED-SAL = 
sedentary saline, n=10; SED-DOX = sedentary doxorubicin, n=10; EXER-SAL = 
exercise saline, n=13; EXER-DOX = exercise doxorubicin, n=14. Values are mean ± 
SEM. 
a = Significantly different from EXER-DOX. 
Significant activity and drug effect in SOL Myf5 (p<0.05). 
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MyoD 
In the SOL, a significant drug effect was observed, with DOX groups exhibiting 
higher levels of MyoD, F (1, 43) = 5.382, p<0.05 (Figure 4.10A). No activity effect and 
no interaction in SOL MyoD were detected. In the EDL, no significant main effects were 
identified, and no interaction was observed (Figure 4.10B). 
 
 
          
Figure 4.10. MyoD expression levels, SOL (A) and EDL (B). 
SOL = soleus, EDL = extensor digitorum longus, OD = optical density, SED-SAL = 
sedentary saline, n=10; SED-DOX = sedentary doxorubicin, n=10; EXER-SAL = 
exercise saline, n=13; EXER-DOX = exercise doxorubicin, n=14. Values are mean ± 
SEM. 
Significant drug effect in SOL MyoD (p<0.05). 
 
Myogenin 
In the SOL, no significant drug or activity effects or interaction were observed 
(Figure 4.11A). In the EDL, no significant main effects or interaction were identified 
(Figure 4.11B). 
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Figure 4.11. Myogenin expression levels, SOL (A) and EDL (B). 
SOL = soleus, EDL = extensor digitorum longus, OD = optical density, SED-SAL = 
sedentary saline, n=10; SED-DOX = sedentary doxorubicin, n=10; EXER-SAL = 
exercise saline, n=13; EXER-DOX = exercise doxorubicin, n=14. Values are mean ± 
SEM. 
 
Muscle Regulatory Factor 4  
In the SOL, a significant activity effect was observed, with EXER groups 
exhibiting higher levels of muscle regulatory factor 4 (Mrf4), F (1, 43) = 5.672, p<0.05 
(Figure 4.12A). No drug effect or interaction in the SOL was detected. In the EDL, no 
significant main effects were identified, and no interaction was observed either (Figure 
4.12B). 
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Figure 4.12. Mrf4 expression levels, SOL (A) and EDL (B). 
SOL = soleus, EDL = extensor digitorum longus, OD = optical density, SED-SAL = 
sedentary saline, n=10; SED-DOX = sedentary doxorubicin, n=10; EXER-SAL = 
exercise saline, n=13; EXER-DOX = exercise doxorubicin, n=14. Values are mean ± 
SEM. 
Significant activity effect in SOL Mrf4 (p<0.05) 
 
Summary 
Acute DOX treatment and short-term endurance exercise did not significantly 
affect skeletal muscle maximal twitch force production in the SOL or EDL. The time 
taken to fatigue in both SOL and EDL was longest in sedentary animals receiving saline 
injections. No absolute measures of tissue mass were significantly different but, after 
correcting for relative mass, an activity main effect was observed with higher EDL 
masses. No mass differences were seen in SOL.  
An activity main effect in the EDL of EXER animals suggests elevated oxidative 
stress as indicated by higher levels of lipid peroxidation. Surprisingly, lipid peroxidation 
levels were higher in the SOL of SAL animals than SOL of DOX animals. Myf5 
expression in the SOL was increased with both drug and exercise treatments. MyoD 
expression in the SOL was increased with DOX treatment. Levels of Mrf4 in the SOL 
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were elevated with endurance training. No change was seen in SOL myogenin levels, and 
no changes in Myf5, MyoD, Mrf4, or myogenin were observed in the EDL due to 
exercise or DOX treatments. 
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CHAPTER V 
MANUSCRIPT FOR PUBLICATION 
Abstract 
Doxorubicin (DOX) is a widely used anthracycline antibiotic used to treat a number of 
hematological and solid tumor cancers. Dosage, however, is limited due to its toxic 
effects in healthy tissues. Negative consequences include myotoxicity in skeletal muscle, 
which may limit mobility and activities of daily living. The capacity for skeletal muscular 
regeneration relies heavily of the activity of myogenic regulatory factor (MRF) proteins. 
In vitro experiments with DOX depress the expression of MRFs but in vivo treatment 
may elicit different responses. Endurance exercise has been shown to elevate MRF 
expression, and may preserve MRFs following in vivo DOX-treatment. 
Purpose: To determine the effect of short-term endurance training and acute DOX 
administration of skeletal muscle force production and fatigue resistance, levels of lipid 
peroxidation, and expression of MRFs. Methods: Ten week old male Sprague-Dawley 
rats were randomly assigned to one of four groups: sedentary + saline (SED-SAL), SED-
DOX, endurance exercise training + saline (EXER-SAL), or EXER-DOX. Animals 
remained sedentary or performed treadmill training for two weeks. Twenty four hours 
after the activity period, animals were injected with a bolus i.p. injection of DOX (15 
mg/kg) or SAL. Twenty four hours after injection, soleus (SOL) and extensor digitorum 
longus (EDL) skeletal muscles were removed for ex vivo function measures. Analyses of 
lipid peroxidation (malondialdehyde and 4-hydroxyalkenals [MDA + 4-HAE]) and 
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Western blotting for MRF expression (Myf5, MyoD, myogenin, Mrf4) were performed 
on contralateral muscles.  Endurance exercise significantly elevated Myf5 and Mrf4 in 
the SOL (p<0.05). No significant differences existed in MRF expression levels in the 
EDL. No significant muscle force production or fatigue resistance differences were 
identified due to drug or activity treatment. MDA + 4-HAE was higher in the SOL of 
SAL animals (p<0.05) and EDL of EXER animals (p<0.05). Conclusion: Short-term 
endurance exercise elevated Myf5 and Mrf4 in slow, oxidative muscle after acute DOX 
treatment. Endurance exercise prior to chemotherapy may augment skeletal muscles’ 
regenerative capacity following treatment, when loss of muscle mass is common. 
Introduction 
 Muscle weakness and subsequent deterioration in activities of daily living are 
common side effects of chemotherapy treatments prescribed to cancer patients (Bonifati 
et al., 2000; Burckart, Beca, Urban, & Sheffield-Moore, 2010; Knobel et al., 2001). The 
commonly used anthracycline antibiotic, doxorubicin (DOX; trade name: Adriamycin®) 
has been shown to elicit consequences, which precede severe to fatal associations with its 
cardiotoxic nature. Free radicals formed by iron-catalyzed reactions are implicated in 
nuclear and mitochondrial damage inducing cell death (Bagchi, Bagchi, Hassoun, Kelly, 
& Stohs, 1995; DeAtley et al., 1999; Rapozzi et al., 1998; Stathopoulos et al., 1997). 
Much of the existing literature surrounding DOX-induced injury focuses on the effects 
seen in the heart. More recently, research has elucidated serious skeletal muscle harm, 
decreasing muscle size and function in response to DOX exposure (Doroshow, Tallent, & 
Schechter, 1985; Gilliam et al., 2009; Gilliam et al., 2013; Gilliam, Moylan, Callahan, 
Sumandea, & Reid, 2011). Previous research has demonstrated the beneficial influence of 
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endurance exercise preconditioning in mitigating the negative cardio- and myotoxic 
consequences of DOX treatment (Ascensão, Oliveira, & Magalhães, 2012; Chicco, 
Schneider, & Hayward, 2006; Hayward, Lien, Jensen, Hydock, & Schneider, 2012; 
Hydock, Lien, Jensen, Schneider, & Hayward, 2011b). 
 Skeletal muscle comprises a large part of the human body and is responsible for 
posture and locomotion. It is unique in its plasticity to alter its form following various 
stimuli. In adult muscle, myogenic regulatory factors (MRFs) guide satellite cells to 
restore muscle integrity in response to damage and stress, such as exercise. Activated 
satellite cells, expressing primary MRFs, form myoblasts, and differentiate into myotubes 
in response to secondary MRFs and reconstitute muscle fibers. The ability of skeletal 
muscle to repair itself and retain structure relies heavily on functional MRF proteins.  
 In vitro DOX exposure has been shown to decrease the ability of myoblasts to 
differentiate into myotubes (Kurabayashi, Jeyaseelan, & Kedes, 1993). Additionally, 
MRF mRNA expression is compromised under the same conditions with an up-regulation 
of the MRF inhibitor, Id (Kurabayashi, Jeyaseelan, & Kedes, 1994). DOX has been 
shown to induce oxidative stress, leading to cellular damage and single-stranded DNA 
breaks. Beyond oxidative damage, genotoxic stress attributed to DOX leads to double-
stranded DNA breaks. The primary MRF, MyoD, is fundamentally involved in myoblast 
DNA repair (Kobayashi, Antoccia, Tauchi, Matsuura, & Komatsu, 2004). Its presence, 
along with the other MRFs, is critical for skeletal muscle regeneration following 
chemotherapy treatment which includes DOX. Prior endurance exercise training may also 
influence the expression of MRFs in skeletal muscle. Following endurance training, SOL 
of rats express elevated levels of oxidative enzyme genes and myogenin (Siu, Donley, 
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Bryner, & Alway, 2004). Although MRF mRNA has been broadly investigated, protein 
expression has been less examined.  
 The purpose of this study was to test whether a two-week treadmill protocol prior to 
acute DOX administration would preserve skeletal muscle function (twitch force and 
fatigue resistance) and decrease levels of lipid peroxidation. It was hypothesized that 
DOX treatment would impair skeletal muscle force production and fatigue resistantce 
while increasing lipid peroxidation. These decrements were predicted to be attenuated 
with short-term aerobic preconditioning. In combination with elevated antioxidant 
enzymes with short-term aerobic exercise, increased MRF protein may effectively 
mitigate the skeletal muscle dysfunction attributed to DOX treatment and enhance 
subsequent repairs. A tertiary hypothesis of this study postulated that exercise training 
would elevate MRF concentrations in the SOL and EDL.  
Materials and Methods 
Experimental Design 
 Ten week old male Sprague-Dawley rats (Harlan: Indianapolis, IN; N=47) were 
housed in pairs under a 12:12 hour light-dark cycle at room temperature (20 ± 2°C). Rats 
were provided food (Harlan Taklad 2026 rat chow) and distilled water ad libitum. All 
experimental procedures were approved by the University of Northern Colorado 
Institutional Animal Care and Use Committee (Protocol #1407C-DH-R-17) and were in 
compliance with the Animal Welfare Act guidelines.  
Rats were randomly assigned to sedentary (SED) (n=20) or treadmill exercise 
(EXER) (n=27) groups. The SED group was limited to normal cage activity for the 
duration of the study. Animals in the EXER group were exercised progressively on a 
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motorized treadmill at 30 m/min through week 1 and for one hour during week 2 (Table 
5.1). When necessary, rats were motivated by light electric shock at the rear of treadmill 
lanes. All EXER subjects completed the training protocol. 
Table 5.1 
Treadmill exercise training protocol 
Day 1 2 3 4 5 6 – 7  8 - 12 
Speed (m/min) 30 30 30 30 30 (Rest) 30 
Duration (min) 10 20 30 40 50 (Rest) 60 
Incline (%) 0 0 0 0 0 (Rest) 0 
 
Drug Treatment 
 At the completion of the two week activity period, animals were sedentary for 24 
hours. After the 24 hour sedentary period, animals were subdivided to receive DOX or 
saline (SAL) injections: SED-SAL (n=10), SED-DOX (n=10), EXER-SAL (n=13), 
EXER-DOX (n=14). Subjects in the DOX group received a bolus i.p. 15 mg/kg injection 
of DOX hydrochloride (Bedford Labs: Bedford, OH). Animals in the SAL group received 
an equivalent volume of 0.9% saline. 24 hours following injections, animals were 
sacrificed and muscles of interest were removed. 
Tissue Preparation 
Animals were anesthetized with sodium pentobarbital (50 mg/kg), and once a tail 
pinch reflex was absent, soleus (SOL) and extensor digitorum longus (EDL) muscles 
were excised. Muscles from the left leg were flash frozen in liquid nitrogen and stored at   
-80°C for later biochemical analysis. Muscles from the right leg were transferred to a 
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warm organ bath (Radnoti: Monrovia, CA) of Krebs Henseleit buffer (120 NaCl, 5.9 
KCl, 2.5 CaCl2, 1.2 MgCl, 25 NaHCO3, 17 glucose; in mM) for muscle function data 
collection. 
Assessment of Skeletal Muscle Function 
Functional muscle data were obtained via electrostimulation of tissues. Two 
electrodes surrounding the muscle in organ baths provided stimulation. Muscle 
contraction forces were recorded using PowerLab data acquisition hardware 
(ADInstruments: Colorado Springs, CO). Maximal twitch force was achieved by 
adjusting muscle for optimal length, and subsequent change in voltage applied (Grass 
Technologies: Warwick, RI).  
The muscle stimulation methods follow the protocol reported by Hydock et al. 
(2011). Muscles were allowed to stabilize in a warmed (37°C) and oxygenated (95% 
O2/5% CO2) organ bath prior to functional experiments. Initial muscle tension was 
adjusted to 0.5g, and stimulated with a square-wave pulse duration of 0.5 ms at 40V. 
Muscle tension was increased by 0.2g per stimulation (2-minute rest) until twitch force 
reached a maximum. Next, optimal voltage was verified by increasing applied voltage by 
5V, allowing the same 2-minute rest period. Once maximal twitch force was determined, 
the bath of Krebs-Henseleit buffer was cycled to ensure proper electrolyte balance for the 
ensuing fatigue recording. The muscle was allowed a recovery time of 30 minutes in 
fresh buffer before continuous stimulation cycling. Pulse duration was increased to 500 
ms while maintaining the determined optimal length and voltage. The muscle was 
stimulated continuously every 1 second for 2 minutes to simulate fatiguing conditions 
(Hydock, Lien, Jensen, Schneider, & Hayward, 2011a). LabChart software 
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(ADInstruments) was used to analyze force data acquired. 
Measures of maximal force, maximal rate of force development, and maximal rate 
of force decline were recorded during the single twitch force stimulation recordings. 
During the continuous, fatiguing protocol, force production was recorded in reference to 
baseline levels every 10 seconds, for a total of 100 seconds.   
Biochemical Analysis 
Flash frozen left hindlimb muscles were homogenized and sonicated in 
radioimmunoprecipitation assay (RIPA) buffer (10:1) and protease enzyme inhibitors 
(SigmaAldrich: St. Louis, MO). Homogenates were then spun in a microcentrifuge for 10 
minutes at 3000g at 4°C. Total protein was quantified and standardized in samples 
according to the bicinchronic acid (BCA) assay (Smith et al., 1985).  
Lipid Peroxidation 
 The most abundant product of LPO is malondialdehyde (MDA), and it is 
commonly assayed as an index of oxidative stress. LPO was determined using a 
commercially available assay kit (BioxyTech MDA-586, Oxis Research: Foster City, 
CA). Malondialdehyde and 4-hydroxyalkenals (MDA+4-HAE) were measured to 
indicate cellular lipid peroxidation. Two hundred µL of sample homogenate was added to 
a microcentrifuge tube. Six hundred-fifty µL of N-methyl-2-phenylindole in acetonitrile 
was added to the sample and briefly vortexed. One hundred-fifty µL of methanesulfonic 
acid was then be added and vortexed, followed by a 60 minute incubation period at 45°C. 
Following the incubation period, samples were centrifuged at 10,000g for 10 minutes to 
remove turbidity. Supernatants were then transferred to cuvettes for absorbency 
measurement using a spectrophotometer at 586 nm. Concentration of MDA+4-HAE was 
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estimated from a standard curve. Samples were run in duplicate and reassayed if samples 
varied by more than 5%.  
Western Blotting 
Western blot analysis was conducted on muscle samples for the presence of 
MRFs in the SOL and EDL. An equal volume of Lammeli buffer was added to samples, 
and samples were heated in boiling water for 2 minutes, then chilled on ice for 5 minutes 
before 46 µg of protein was loaded onto 4-20% gradient Tris-Glycine NuPage precast 
gels (LifeTechnologies: Carlsbad, CA). Gels were run at 125 constant voltage and 4 mA 
current for 2 hours in a Xcell II blot module (Invitrogen, LifeTechnologies). Proteins 
were transferred to 0.45 micron polyvinylidene fluoride (PVDF) membranes over 90 
minutes at 25 volts and 100 mA. Band transfers to PVDF membranes were ensured by 
the presence of a SeeBlue® Plus2 protein ladder (Novex, LifeTechnologies). Membranes 
were blocked for 1 hour in 15 mL of TBST + 5% milk, and then incubated with gentle 
agitation overnight in 10 mL of primary antibodies. Membranes were then washed in 
TBST three times for 5 minutes, followed by incubation in appropriate species-specific 
secondary antibodies for 1 hour. After three more 5-minute washes in TBST, membranes 
were prepared for protein band detection.  
Detection was executed by enhanced chemiluminescence (ECL) (C-Digit, Li-Cor: 
Lincoln, NE), and ImageJ software (NIH: Bethesda, MD) was used to quantify the 
protein bands. Immediately before chemiluminescent imaging, 1.5 mL of luminol and 
enhancer (SuperSignal West Femto Maximum Sensitivity Chemiluminescent Substrate, 
ThermoScientific: Waltham, MA) was added to the membrane. The primary antibodies of 
interest included rabbit monoclonal MyoD, myogenin (Santa Cruz Biotechnology: 
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Dallas, TX), Myf5, and Mrf4 (Abcam: Cambridge, MA). The rabbit monoclonal anti-
GAPDH (Abcam) was used as a loading control. Molecular weights of protein bands 
were ensured in reference to a MagicMark™ XP standard ladder (Novex, 
LifeTechnologies). Secondary antibodies (Santa Cruz Biotechnology) corresponded to 
associated species (rabbit) and include horseradish peroxidase (HRP) for adequate 
reactivity. 
Statistical Analysis 
Data were analyzed and presented using GraphPad Prism statistical software 
(GraphPad: LaJolla, CA). Variables analyzed were assessed as means ± standard error 
(mean±SE). A two-factor (Exercise X Drug) analysis of variance (ANOVA) was used to 
determine main effects and interactions of treatments in muscle mass, muscle force 
production, lipid peroxidation, and MRF concentration. If a significant F-value was 
observed, a Tukey post-hoc pair-wise comparison identified significant differences 
between groups. Variables included the four MRF proteins concentrations, muscle 
masses, and force parameters from ex vivo analysis in each of the groups (maximal 
twitch, maximal rate of force production, and maximal rate of force decline). Muscle 
fatigue responses were analyzed with maximal twitch force obtained every 10 seconds, 
and compared to baseline twitch force (0 sec). Fatigue was determined to be when force 
production fell below 75% of baseline values. For all procedures, significance was set at 
the α=0.05 level. 
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Results 
General Observations 
Table 5.2 presents animal characteristics at the time of injection and at the time of 
sacrifice. At the time of injection, animal body mass was significantly different between 
groups. An activity effect was observed with SED animals exhibiting significantly greater 
body mass, F (1, 43) = 16.72, p<0.05. Post hoc testing revealed body mass to be higher in 
SED-SAL and SED-DOX than EXER-SAL, p<0.05. 
 
Table 5.2  
Animal Characteristics. 
 SED-SAL   SED-DOX  EXER-SAL  EXER-DOX 
Injection Mass (g)  359.5 ± 11.3 a 364.4 ± 9.9 a 322.1 ± 5.2 335.0 ± 6.8 
Sacrifice Mass (g)  360.4 ± 11.9 b 353.9 ± 9.0 b 325.5 ± 6.3 328.5 ± 6.1 
SOL Mass (mg) 134.9 ± 6.6 140.4 ± 4.4 131.5 ± 5.1 132.9 ± 4.6 
EDL Mass (mg) 142.0 ± 4.8 138.3 ± 7.6 135.2 ± 3.6 140.9 ± 3.6 
SED-SAL = sedentary saline, n=10; SED-DOX = sedentary doxorubicin, n=10; EXER-
SAL = exercise saline, n=13; EXER-DOX = exercise doxorubicin, n=14. Values are 
means ± SEM. 
a = Significantly greater than EXER-SAL (p<0.05). 
b = Significantly greater than EXER-DOX (p<0.05). 
Significant activity effect in injection and sacrifice body mass (p<0.05). 
 
At the time of sacrifice, a similar activity effect existed with greater mass in SED 
animals, F (1, 43) = 13.42, p<0.05. Post hoc testing revealed that EXER-DOX body mass 
was significantly less than SED-SAL and SED-DOX, p<0.05. A significant drug effect 
was observed in body mass change as well, F (1.43) = 34.65, p<0.05 (Figure 5.1). Rats 
receiving SAL slightly gained body mass after injections (1%) while those receiving 
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DOX decreased body mass (2.5%). Within groups, body mass changes were not 
significantly different (p>0.05).  Reductions in body mass of DOX-treated animals may 
be attributed to significantly less food intake within 24 hour following injections (Gilliam 
et al., 2009). 
 
 
Figure 5.1. Change in body mass following injections.  
SED-SAL = sedentary saline, n=10; SED-DOX = sedentary doxorubicin, n=10; EXER-
SAL = exercise saline, n=13; EXER-DOX = exercise doxorubicin, n=14. Values are 
mean ± SEM. 
a = Significantly different from EXER-SAL (p<0.05). 
b = Significantly different from SED-SAL (p<0.05). 
 
 There was no significant difference in absolute SOL mass observed between 
groups, p>0.05 (Figure 5.2A). Similarly, when SOL mass was corrected for body mass, 
no significant difference was detected, p>0.05 (Table 5.3, Figure 5.3A). Absolute EDL 
masses displayed no significant differences for main effects or exercise by drug 
interaction, p<0.05 (Figure 5.2B). When corrected for body mass, an activity effect was 
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detected with endurance-trained animals demonstrating higher relative EDL mass, F = (1, 
43) = 4.871, p<0.05 (Figure 5.3B).  
 
 
Figure 5.2. Tissue mass at time of sacrifice, SOL (A) and EDL (B).  
SOL = soleus, EDL = extensor digitorum longus, SED-SAL = sedentary saline, n=10; 
SED-DOX = sedentary doxorubicin, n=10; EXER-SAL = exercise saline, n=13; EXER-
DOX = exercise doxorubicin, n=14. Values are mean ± SEM. 
 
Table 5.3 
Tissue mass relative to body mass. 
  SED-SAL  SED-DOX EXER-SAL EXER-DOX 
SOL (mg/g BM) 0.37 ± 0.01 0.39 ± 0.01  0.40 ± 0.01 0.41 ± 0.01 
EDL (mg/g BM) 0.39 ± 0.01 0.39 ± 0.02  0.42 ± 0.01 0.43 ± 0.01 
SOL = soleus, EDL = extensor digitorum longus, SED-SAL = sedentary saline, n=10; 
SED-DOX = sedentary doxorubicin, n=10; EXER-SAL = exercise saline, n=13; EXER-
DOX = exercise doxorubicin, n=14. Values are mean ± SEM. 
a = Significantly different from EXER-SAL (p<0.05). 
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Figure 5.3. Tissue mass relative to body mass, SOL (A) and EDL (B). 
SOL = soleus, EDL = extensor digitorum longus, BM = body mass, SED-SAL = 
sedentary saline, n=10; SED-DOX = sedentary doxorubicin, n=10; EXER-SAL = 
exercise saline, n=13; EXER-DOX = exercise doxorubicin, n=14. Values are mean ± 
SEM. 
 
Isolated Muscle Function 
Maximal Twitch Force. Once right SOL and EDL were excised, muscles were 
placed in organ baths filled with Krebs-Henseleit buffer. Tension and voltage were 
gradually increased to determine optimum conditions as detected by maximal twitch 
force elicited. Additionally, maximal rate of force production and maximal rate of force 
decline were measured from maximal twitch force tracings. 
No significant differences were observed in SOL maximal twitch forces between 
groups, p>0.05 (Table 5.4). After adjusting force relative to tissue mass, significance 
remained undetected (Figure 5.4).  Rates of force production and decline were also not 
significantly different between groups, p<0.05.  
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Table 5.4 
SOL muscle twitch forces 
       SED-SAL      SED-DOX    EXER-SAL   EXER-DOX 
Maximal Twitch 
Force (mN) 
        37 ± 3        50 ± 5        44 ± 4       46 ± 4 
Relative Maximal 
Twitch Force 
(mN/g) 
      249 ± 36      287 ± 29      258 ± 28     296 ± 41 
Maximal Rate of 
Force Production 
(mN/s) 
    4916 ± 463    6376 ± 699    5478 ± 670   5536 ± 589 
Maximal Rate of 
Force Decline 
(mN/s) 
  - 1715 ± 193  - 1935 ± 160  - 2027 ± 117 - 2255 ± 154 
SOL = soleus, SED-SAL = sedentary saline, n=10; SED-DOX = sedentary doxorubicin, 
n=10; EXER-SAL = exercise saline, n=13; EXER-DOX = exercise doxorubicin, n=14. 
Values are mean ± SEM. 
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Figure 5.4. SOL Maximal twitch force values. Maximal twitch (A), maximal twitch 
relative to tissue mass (B), rate of force production (C), rate of force production (D), SOL 
rate of force decline. 
SOL = soleus, SED-SAL = sedentary saline, n=10; SED-DOX = sedentary doxorubicin, 
n=10; EXER-SAL = exercise saline, n=13; EXER-DOX = exercise doxorubicin, n=14. 
Values are mean ± SEM. 
 
No significant differences were seen between groups in EDL maximal twitch 
forces, p>0.05 (Table 5.5). Similarly, no significance was observed after correcting for 
tissue mass. Rates of force production and decline were not significantly different 
between groups, as well (Figure 5.5). 
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Table 5.5 
EDL muscle twitch forces 
      SED-SAL       SED-DOX     EXER-SAL   EXER-DOX 
Maximal Twitch 
Force (mN) 
       79 ± 7         90 ± 9         92 ± 8      77  ± 12 
Relative Maximal 
Twitch Force 
(mN/g) 
     511 ± 26       603 ± 69       632 ± 51     545 ± 80 
Maximal Rate of 
Force Production 
(mN/s) 
 14407 ± 1199   17851 ± 2060   18242 ± 1772 14966 ± 2603 
Maximal Rate of 
Force Decline 
(mN/s) 
- 8489 ± 690 - 10410 ± 1155 - 11583 ± 1272 - 9308 ± 1380 
EDL = extensor digitorum longus, SED-SAL = sedentary saline, n=10; SED-DOX = 
sedentary doxorubicin, n=10; EXER-SAL = exercise saline, n=13; EXER-DOX = 
exercise doxorubicin, n=14. Values are mean ± SEM. 
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Figure 5.5. EDL Maximal twitch force values. Maximal twitch (A), maximal twitch 
relative to tissue mass (B), rate of force production (C), rate of force production (D), SOL 
rate of force decline. 
EDL = extensor digitorum longus, SED-SAL = sedentary saline, n=10; SED-DOX = 
sedentary doxorubicin, n=10; EXER-SAL = exercise saline, n=13; EXER-DOX = 
exercise doxorubicin, n=14. Values are mean ± SEM. 
 
Fatigue. After cycling Krebs-Henseleit buffer and allowing muscles to rest for 30 
minutes, a 2-minute continuous stimulation at determined optimal length and voltage was 
performed. Time-to-fatigue was determined when muscles produced 75% of baseline 
force production. 
 In the SOL, SED-DOX and EXER-SAL generated less than 75% baseline force 
40 seconds into fatiguing protocol. At the 50-second time point, EXER-DOX force 
production was below 75%. SED-SAL recorded the greatest fatigue resistance with 
twitch forces lower than 75% of baseline by 70 seconds (Figure 5.6). 
SE
D
EX
ER
0
50
100
150
Fo
rc
e 
(m
N
)
A
SE
D
EX
ER
0
5000
10000
15000
20000
25000
R
at
e 
of
 F
or
ce
 P
ro
du
ct
io
n 
(m
N
/s
) C
SE
D
EX
ER
0
200
400
600
800
Fo
rc
e 
(m
N
)
B
SAL
DOX
SE
D
EX
ER
-15000
-10000
-5000
0
R
at
e 
of
 F
or
ce
 D
ec
lin
e 
(m
N
/s
)
D
	 83 
	
 
	
Figure 5.6. SOL fatigue resistance.  
SOL = soleus, SED-SAL = sedentary saline, n=10; SED-DOX = sedentary doxorubicin, 
n=10; EXER-SAL = exercise saline, n=13; EXER-DOX = exercise doxorubicin, n=14. 
Values are means ± SEM. 
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In the EDL, SED-SAL fatigued quickest with twitch forces less than 75% at the 
40-second time point. SED-DOX, EXER-SAL, and EXER-DOX groups’ forces fell 
below fatigue threshold at 50 seconds (Figure 5.7). The fast-twitch muscle typically 
fatigues a greater rate than slow, oxidative muscles. Ex vivo force production of the EDL 
did not fatigue faster to levels below 75% of initial force values but, at the end 100 
seconds, all groups’ twitch forces were below those of the SOL. 
The short-term duration of training may not have been long enough to 
accommodate appreciable fatigue resistance in SOL of EXER animals receiving DOX. 
Additionally, with greater time passing after DOX treatment functional deficits are 
evident. The 24 hours following injection may not have been enough to elucidate effects. 
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Figure 5.7. EDL fatigue resistance. 
EDL = extensor digitorum longus, SED-SAL = sedentary saline, n=10; SED-DOX = 
sedentary doxorubicin, n=10; EXER-SAL = exercise saline, n=13; EXER-DOX = 
exercise doxorubicin, n=14. Values are means ± SEM. 
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Biochemical Analyses 
Lipid Peroxidation. SOL and EDL homogenates obtained from rats 1 day after 
saline or DOX injection were analyzed for markers of lipid peroxidation (MDA+4-HAE). 
All data from LPO analysis are presented in Table 5.6. In SOL, a significant drug effect 
was observed. Rats receiving SAL exhibited higher levels of MDA+4-HAE than DOX 
animals, F = (1, 43), p<0.05 (Figure 5.8A). Post hoc analyses identified EXER-SAL 
animals to express significantly greater indices of lipid peroxidation than SED-DOX and 
EXER-DOX. No activity effect or interaction was detected in the SOL. In the EDL, a 
significant activity effect was observed with TM animals presenting higher MDA+4-
HAE, F = (1, 43) = 4.08, p<0.05 (Figure 5.8B). No drug effect or interaction was 
detected. The activity effect seen in EDL of EXER animals may have been due to stress 
of treadmill training on largely glycolytic muscles. 
 
Table 5.6 
Lipid peroxidation levels 
 SED-SAL SED-DOX EXER-SAL EXER-DOX 
SOL (pmol/mg)  329 ± 24 275 ± 17 a   398 ± 36   292 ± 17 a 
EDL (pmol/mg)  214 ± 14 225 ± 17   283 ± 28   288 ± 44 
SOL = soleus, EDL = extensor digitorum longus, SED-SAL = sedentary saline, n=10; 
SED-DOX = sedentary doxorubicin, n=10; EXER-SAL = exercise saline, n=13; EXER-
DOX = exercise doxorubicin, n=14. Values are mean ± SEM. 
a = Significantly different from EXER-SAL (p<0.05). 
Significant drug effect in the SOL (p<0.05). 
Significant activity effect in the EDL (p<0.05). 
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Figure 5.8. Lipid peroxidation levels in hindlimb muscles, SOL (A) and EDL (B). 
SOL = soleus, EDL = extensor digitorum longus, SED-SAL = sedentary saline, n=10; 
SED-DOX = sedentary doxorubicin, n=10; EXER-SAL = exercise saline, n=13; EXER-
DOX = exercise doxorubicin, n=14. Values are mean ± SEM. 
a = Significantly different from EXER-SAL. 
Significant drug effect in SOL (p<0.05). 
Significant activity effect in EDL (p<0.05). 
 
Western Blotting. Expression of myogenic regulatory factor proteins, Myf5, 
MyoD, Mrf4, and myogenin, were measured in SOL and EDL homogenates to evaluate 
the influence of endurance exercise and DOX on these transcription factors. Forty-six µg 
protein from SOL and EDL homogenates were added to 4-20% Tris-glycine precast gels 
and run through SDS-PAGE. MRF levels were assessed by chemiluminescence and 
expressed relative to GAPDH as a loading control. It should be noted that no significant 
GAPDH activity and drug main effects or interactions (p>0.05) were observed suggesting 
that the exercise or drug treatments did not affect the loading control. All Western blot 
data are presented in Tables 5.7 (SOL) and 5.8 (EDL). 
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Table 5.7 
SOL MRF levels 
  SED-SAL  SED-DOX EXER-SAL EXER-DOX 
Myogenic Factor 5 
(Myf5)  
0.44 ± 0.10 a 0.73 ± 0.14 0.92 ± 0.08 1.28 ± 0.22 
MyoD 1.29 ± 0.13 1.67 ± 0.13 1.46 ± 0.16 2.11 ± 0.31 
Myogenin 0.50 ± 0.12 0.67 ± 0.14 0.81 ± 0.17 0.80 ± 0.16 
Muscle Regulatory 
Factor 4 (Mrf4) 
0.62 ± 0.18 0.80 ± 0.20 1.23 ± 0.18 1.22 ± 0.24 
SOL = soleus, SED-SAL = sedentary saline, n=10; SED-DOX = sedentary doxorubicin, 
n=10; EXER-SAL = exercise saline, n=13; EXER-DOX = exercise doxorubicin, n=14. 
Values are mean ± SEM. 
a = Significantly different from EXER-DOX (p<0.05). 
Significant activity and drug effect in Myf5 (p<0.05). 
Significant drug effect in MyoD (p<0.05). 
Significant effect effect in Mrf4 (p<0.05). 
 
Table 5.8 
EDL MRF levels 
  SED-SAL  SED-DOX EXER-SAL EXER-DOX 
Myogenic Factor 5 
(Myf5)  
1.25 ± 0.23 1.25 ± 0.19 1.57 ± 0.19 1.49 ± 0.14 
MyoD 1.28 ± 0.20 1.55 ± 0.17 1.30 ± 0.07 1.13 ± 0.09 
Myogenin 0.48 ± 0.15 0.64 ± 0.15 0.62 ± 0.11 0.67 ± 0.14 
Muscle Regulatory 
Factor 4 (Mrf4) 
0.47 ± 0.12 0.52 ± 0.13 0.64 ± 0.09 0.46 ± 0.08 
EDL = extensor digitorum longus, SED-SAL = sedentary saline, n=10; SED-DOX = 
sedentary doxorubicin, n=10; EXER-SAL = exercise saline, n=13; EXER-DOX = 
exercise doxorubicin, n=14. Values are mean ± SEM. 
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Myogenic Factor 5. In the SOL, a 2-way ANOVA revealed a significant activity 
effect, with EXER groups exhibiting higher levels of myogenic factor 5 (Myf5), F (1, 43) 
= 10.42, p<0.05 (Figure 5.9A). Additionally, a drug effect was observed, with DOX-
treated groups expressing higher Myf5, F (1, 43) = 4.267, p=<0.05. No significant 
interaction was observed. Post hoc tests revealed that SED-SAL expressed significantly 
less Myf5 than EXER-DOX. 
In the EDL, no significant main effects were observed (Figure 5.9B). No 
interaction was seen in the EDL, and no interaction was detected. 
 
 
             
Figure 5.9. Myf5 expression levels, SOL (A) and EDL (B). 
SOL = soleus, EDL = extensor digitorum longus, OD = optical density, SED-SAL = 
sedentary saline, n=10; SED-DOX = sedentary doxorubicin, n=10; EXER-SAL = 
exercise saline, n=13; EXER-DOX = exercise doxorubicin, n=14. Values are mean ± 
SEM. 
a = Significantly different from EXER-DOX. 
Significant activity and drug effect in SOL Myf5 (p<0.05). 
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MyoD. In the SOL, a significant drug effect was observed, with DOX groups 
exhibiting higher levels of MyoD, F (1, 43) = 5.382, p<0.05 (Figure 5.10A). No activity 
effect and no interaction in SOL MyoD were detected. In the EDL, no significant main 
effects were identified. and no interaction was observed (Figure 5.10B).  
 
 
          
Figure 5.10. MyoD expression levels, SOL (A) and EDL (B). 
SOL = soleus, EDL = extensor digitorum longus, OD = optical density, SED-SAL = 
sedentary saline, n=10; SED-DOX = sedentary doxorubicin, n=10; EXER-SAL = 
exercise saline, n=13; EXER-DOX = exercise doxorubicin, n=14. Values are mean ± 
SEM. 
Significant drug effect in SOL MyoD (p<0.05). 
 
Myogenin. In the SOL, no significant drug or activity effects were observed 
(Figure 5.11A). In the EDL, no significant main effects or interaction were identified 
(Figure 5.11B).  
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Figure 5.11. Myogenin expression levels, SOL (A) and EDL (B). 
SOL = soleus, EDL = extensor digitorum longus, OD = optical density, SED-SAL = 
sedentary saline, n=10; SED-DOX = sedentary doxorubicin, n=10; EXER-SAL = 
exercise saline, n=13; EXER-DOX = exercise doxorubicin, n=14. Values are mean ± 
SEM. 
 
Muscle Regulatory Factor 4. In the SOL, a significant activity effect was 
observed, with EXER groups exhibiting higher levels of muscle regulatory factor 4 
(Mrf4), F (1, 43) = 5.672, p=0.0217 (Figure 5.12A). No drug effect or interaction in the 
SOL was detected. In the EDL, no significant main effects were identified, and no 
interaction was observed either (Figure 5.12B). 
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Figure 5.12. Mrf4 expression levels, SOL (A) and EDL (B). 
SOL = soleus, EDL = extensor digitorum longus, OD = optical density, SED-SAL = 
sedentary saline, n=10; SED-DOX = sedentary doxorubicin, n=10; EXER-SAL = 
exercise saline, n=13; EXER-DOX = exercise doxorubicin, n=14. Values are mean ± 
SEM. 
Significant activity effect in SOL Mrf4 (p<0.05). 
 
Discussion 
This is the first study to assess endurance exercise training and in vivo DOX 
effects on MRF expression in skeletal muscle. It was hypothesized that a two-week 
treadmill protocol prior to acute DOX administration would preserve muscle twitch 
forces and fatigue resistance, decrease levels of lipid peroxidation, and enhance MRF 
concentrations. The major findings are that 1) exercise did not alter muscle force 
parameters, 2) LPO was elevated in SAL-treated SOL and EXER group EDL, and 3) 
exercise training elevated Myf5 and Mrf4 levels in the SOL and acute DOX treatment 
increased Myf5 and MyoD in the SOL. 
EXER animals had lower body masses than SED animals after two weeks of 
treadmill exercise, which may be attributed to increased caloric expenditure. Absolute 
and relative muscle tissue masses were not significantly reduced in DOX-treated groups 
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compared with acute SAL treatment. Previous studies identify DOX-induced decreases in 
muscle mass, but these losses are typically seen after 3 days (Doroshow et al., 1985). 
Within group body masses did not significantly differ, which is consistent with similar 
studies involving acute DOX exposure (Wonders, Hydock, Schneider, & Hayward, 
2008). 
Regarding skeletal muscle function, no significant differences were observed in 
either SOL or EDL as measures of ex vivo maximal twitch force. The present data 
suggest that acute DOX treatment did not reduce force production in hindlimb muscles 
one day following DOX injection. SED-DOX groups trended toward slightly better 
performance than SED-SAL in all maximal twitch measures (max force, rate of force 
development, rate of force decline). Previous studies have shown Ca2+ release to increase 
without changing Ca2+ sensitivity in muscle fibers exposed to DOX (Chugun et al., 2000; 
Zorzato, Salviati, Facchinetti, & Volpe, 1985). Failure of SR reuptake of Ca2+ may 
increase force produced during contractions, which may explain the trend toward slightly 
higher SED-DOX muscle twitch forces compared to SED-SAL (MacLennan, 2000).  
Although two weeks of endurance exercise in SAL animals trended toward 
slightly higher force production, variables were not significantly different. DOX groups 
showed no significant differences in force production due to exercise preconditioning. In 
the SOL, SED-SAL took longest to fatigue below 75% of baseline force (70 sec), while 
SED-DOX and EXER-SAL fatigued quickest (40 sec). Conversely, the EDL of SED-
SAL animals produced forces below the fatigue point (75%) ten seconds before all other 
groups (40 vs 50 sec). A study employing an equivalent dosage by Hydock et al. (2011) 
demonstrated significantly less twitch force, maximal rate of force production, and 
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maximal rate of force decline in DOX-treated animals five days following injections. The 
time period following DOX administration in this study may have been too brief to 
induce significant functional deficits. Additionally, exercise-induced injury of skeletal 
muscle without adequate time for recovery may explain EXER-SAL decrements in 
fatigue resistance of SOL. A previous study examining skeletal muscle damage 
associated with running reported degeneration, necrosis and phagocytosis shortly after 
and during 2 weeks following the onset of exercise (Irintchev & Wernig, 1987). 
The generation of reactive oxygen species has been implicated as a mechanism of 
DOX’s antineoplastic actions (Minotti, Menna, Salvatorelli, Cairo, & Gianni, 2004). As a 
side effect of DOX treatment, uncontrolled ROS production can induce LPO, damage to 
cell membranes and organelles, disrupted signaling pathways, apoptosis, and muscle 
atrophy (Chance, Sies, & Boveris, 1979). Additionally, ROS have been shown to 
stimulate Ca2+ release from skeletal muscle SR and affect the regulation of K+ channels 
in muscle tissues (Favero, Zable, & Abramson, 1995; Hool, Di Maria, Viola, & Arthur, 
2005; Tang, Santarelli, Heinemann, & Hoshi, 2004). Interestingly, LPO levels in the SOL 
indicated a drug effect, with SAL groups presenting higher levels of MDA + 4-HAE. The 
predominantly fast, glycolytic EDL of EXER groups exhibited greater levels of lipid 
peroxidation than SED, which may be expected due to increased oxidative activity with 
treadmill running. ROS production signals pathways to promote skeletal muscle 
adaptations following exercise (Franco, Odom, & Rando, 1999; Li, Chen, Li, & Reid, 
2003). If training periods were extended, a significant increase in SOL MDA+4-HAE 
content with exercise may have also been observed as a previous study by Liu et al. 
(2000) demonstrated both fast and slow muscle MDA content to be elevated following 
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chronic treadmill training in rats versus sedentary and acutely-trained animals. Human 
and rat studies suggest repeated exercise induces increased antioxidant levels and enzyme 
activity, which handle free radicals and reduce lipid peroxidation (Dekkers, Van Dooren, 
& Kemper, 1996). DOX administration did not elevate levels of MDA + 4-HAE at one 
day post-injection. The acute time point following injections (1 day) may not have 
allowed for significant DOX-associated lipid peroxidation of cell membranes to occur. 
Expression of MRFs is required for the regeneration of muscle fibers in response 
to trauma or injury. These proteins direct satellite cells for myogenic lineage and 
differentiation into formed myotubes. In this study, MRFs were typically elevated in the 
SOL of DOX animals that performed endurance exercise compared to sedentary 
counterparts. Significant main activity effects were detected in Myf5 and Mrf4 with 
treadmill training. Myf5 may be critical to reestablish satellite cells for skeletal muscle 
regeneration following bouts of chemotherapy, and reducing muscle mass losses. The 
main activity effect was observed in DOX-treated rats that exercise trained as they 
expressed 75% more Myf5 than their SED counterparts. Additionally, EXER-SAL rats 
expressed 109% more Myf5 than SED-SAL.  
A main activity effect was seen with increased Mrf4 expression following 
treadmill training. EXER-DOX expressed 51% more Mrf4 than SED-DOX. EXER-SAL 
rats expressed 99% more Mrf4 than SED-SAL. Increased Mrf4 expression may assist in 
terminal differentiation of new muscle cells. Additionally, Mrf4 has been shown to act 
upstream of MyoD determining cells for muscle identity (Kassar-Duchossoy et al., 2004). 
Taken together, exercise-induced elevations of these two MRFs (Myf5, Mrf4) posit the 
potential for greater muscle regeneration following DOX treatment versus sedentary 
	 96 
	
controls. Although not significant, EXER-DOX trended toward greater concentrations of 
MyoD and myogenin versus SED-DOX (27% and 20%, respectively).  
Given the modality of endurance training, it is understandable that significant 
MRF alterations were observed in the slow, oxidative SOL versus the fast, glycolytic 
EDL. With running exercise, greater stress is placed on oxidative hindlimb muscles. 
Irintchev and Wernig (1987) indicated that voluntary running of mice induces damage in 
the SOL and tibialis anterior muscles, but not the EDL.  
No main effects or interaction were observed in EDL. However, Myf5 and 
myogenin trended to slightly higher expression in EXER-DOX than SED-DOX groups 
(19% and 5%, respectively). In this study, overall MyoD levels were expressed at greater 
concentrations in the SOL than in the EDL (19%). Previous studies show higher MyoD 
mRNA levels in fast, glycolytic muscles (Hughes, Koishi, Rudnicki, & Maggs, 1997). 
The results of the present study may suggest that despite higher MyoD mRNA in Type II 
muscles, expression of the MyoD at the protein level may be higher in Type I fibers. 
Additionally, in vitro studies indicate a depression in MyoD when exposed to DOX 
(Kurabayashi et al., 1993, 1994). Conversely, our results present a drug effect with 
increased levels of MyoD expression in the SOL following DOX injections.  
At time points greater than 24 hours following DOX treatment, reductions in 
MRF expression may occur as mass and function decrease but, the increased levels of 
Myf5 and Mrf4 may alleviate such losses. Along with CD34 and M-cadherin, Myf5 
define quiescent satellite cells commited to myogenesis (Beauchamp et al., 2000). 
Decreased Myf5 expression in cultured cells is marked by decreased proliferation of 
satellite cell-derived myoblasts and delayed differentiation of myotubes (Ustanina, 
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Carvajal, Rigby, & Braun, 2007). Given the expression of Mrf4 at the time around and 
after fusion, elevated protein levels suggest increased skeletal muscle repair (Zhou & 
Bornemann, 2001). Endurance exercise-induced increases in Myf5 and Mrf4 potentially 
improve satellite cell populations and fusion of myotubes thereby attenuating muscle 
mass losses in the SOL after acute DOX treatment. 
Conclusion 
The present study examined the effects of short-term endurance exercise and 
acute DOX administration on skeletal muscle force production, fatigue resistance, LPO, 
and expression of MRFs. Although no remarkable findings were observed in muscle 
function or lipid peroxidation, a significant elevation in the expression of Myf5 and Mrf4 
with endurance training in the SOL was revealed. Myf5 is suggested to replenish satellite 
cell pools and Mrf4 assists in the terminal differentiation of muscle cells (Rudnicki et al. 
2008; Zhu & Miller, 1997).  With increases in these two MRFs, the ability to regenerate 
and repair skeletal muscle may be enhanced in the time following chemotherapy, when 
loss in muscle mass is common. Future research examining parameters at later time 
points following treatment may elicit differential effects, but endurance exercise shows 
promise in upregulating some myogenic transcription factor expression (Myf5, Mrf4) in 
slow, oxidative muscles shortly after acute DOX treatment. Given the importance of 
time-to-chemotherapy and improved clinical outcomes, a short-term endurance exercise 
protocol prior to treatment may provide a feasible measure to prevent muscle mass losses 
seen with chemotherapy in cancer patients (de Melo Gagliato et al. 2014; Doroshow, et 
al., 1985; Gilliam et al., 2009; Gilliam et al., 2013; Gilliam et al., 2011).
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IACUC Memorandum 
 
To: Dr. David Hydock 
From: Laura Martin, Director of Compliance and Operations 
CC: IACUC Files 
Date: 8/26/2014 
Re: IACUC Protocol 1407C-DH-R-17 Approval 
The UNC IACUC has completed a final review of your protocol “Nutrition and Exercise in 
Cancer Treatment-Induced Muscle Dysfunction”.  The protocol review was based on the 
requirements of Government Principles for the Utilization and Care of Vertebrate Animals Used 
in Testing, Research, and Training; the Public Health Policy on Humane Care and Use of 
Laboratory Animals; and the USDA Animal Welfare Act and Regulations.  Based on the review, 
the IACUC has determined that all review criteria have been adequately addressed.  The PI/PD 
is approved to perform the experiments or procedures as described in the identified protocol as 
submitted to the Committee. This protocol has been assigned the following number 1407C-DH-
R-17. 
 
The next annual review will be due before August 26, 2015. 
 
 
Sincerely, 
 
 
 
___________________________________________ 
Laura Martin, Director of Compliance and Operations 
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Pilot Study 
 
Tissue samples of SED-SAL (6) and SED-DOX (6) Sprague-Dawley rats, which 
received injection 5 days prior to sacrifice, were analyzed with Western blot and ECL 
imaging techniques (Figure 1). Compared to SAL-treated animals, the DOX-treated 
group exhibited significantly higher levels of Mrf4 and myogenin in the SOL. A trend for 
decreased Myf5 and MyoD1 expression in the SOL was also observed. The EDL of 
DOX-treated animals exhibited increased levels of Myf5 and MyoD1 and decreased 
expression of Mrf4 just above significance. 
 
 
 
Upon examination of the same hindlimb skeletal muscle tissues of Sprague-
Dawley rats 3 days after injections (Figure 2), Myf5 protein levels appear to be much 
greater in the fast-twitch EDL. When examining Mrf4 levels, bands appear darker in 
slow, oxidative SOL. These samples were not run with a housekeeping protein to ensure 
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protein concentrations of samples were uniform. However, protein samples loaded in 
pilot study were at a concentration of 15 µg. Increased concentrated protein loading will 
likely elicit higher detection of MRFs. Dedkov and colleagues (2003) effectively 
identified MyoD and myogenin proteins with Western blot with similar sample 
concentration (50 µg per lane). 
 
 
 
 
As stated in previous research, a differential expression of MRF proteins exists 
between fibers types, and may play a role in determining phenotypes. Additionally, DOX 
appears to alter levels in SED animals. Both resistance and run exercise has been shown 
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to elevate MRF mRNA levels, but these transcripts return to basal conditions 24 hours 
following single bouts (Psilander et al., 2003; Yang et al., 2005). Given functional MRF 
proteins are expressed after mRNA, their presence should be apparent in periods 
following mRNA expression. However, as shown in denervation studies, mRNA levels 
may increase without satellite cell activation and no change in muscle mass (Dedkov, 
Kostrominova, Borisov, & Carlson, 2001; Sakuma et al., 1999; Voytik et al., 1993; 
Walters, Stickland, & Loughna, 2000). To avoid adaptation to training and return to basal 
levels of Myf5 and Myod, a 2-week training period will be employed. 
Investigating the effects of endurance exercise and DOX treatment on MRF 
protein expression may provide insight to mechanisms potentially preserving skeletal 
muscle adaptation and regenerative capacity. This proposed research is a practical study 
based on supported translational research that can be implemented fairly easily to 
improve health and well-being in an already at-risk patient population.  
